Identification of biomarkers for schizophrenia by Ventura, Vanessa Sofia Santos


  
 
Agradecimentos 
 Ao concluir mais uma etapa da minha vida gostaria de começar por agradecer a quem a 
tornou possível. 
 Ao Professor Dr. Alberto A. C. Canelas Pais por ter aceite este projecto e por toda a ajuda. 
 À Dra. Sandra Nunes por me ter dado a oportunidade de realizar este projecto ao seu 
lado, pela preocupação constante, dedicação, ajuda e todo o apoio recebido ao longo do ano. 
 Ao Dr. Bruno Manadas pela oportunidade de entrar neste projecto, por me ter recebido 
no laboratório e por me permitir evoluir nos meus conhecimentos. 
 À Vera por toda a paciência nos momentos de desespero, pela dedicação, pelo apoio e 
pelo conhecimento transmitido. 
 Um obrigado também às minhas colegas de laboratório. À Catia e à Sandra por toda a 
ajuda, especialmente nos comandos de procura, foram preciosos. À Mariana pela boa 
disposição e simpatia recebida desde o início. À Carolina, ao Nuno, à Margarida e à Joana 
pelos inúmeros momentos de lazer, pelas gargalhadas e sobretudo pela amizade, um 
obrigado muito especial. E ainda, à Tânia Firmino, do Departamento de Química, por toda a 
ajuda e conhecimentos transmitidos nesta etapa final do projecto. 
  À Ana e a Mariana que mesmo distante, nunca desistiram de mim e permaneceram 
sempre ao meu lado. À Maria, ao Ricardo e ao Serrano pelos momentos partilhados ao longo 
de seis anos, porque estiveram do início ao fim e terminam esta etapa ao meu lado. Aos meus 
afilhados, Bernardo e Kika, porque mesmo ausente também nunca esqueceram a madrinha. 
Um obrigado a todos por estarem sempre ao meu lado. 
 À família por estar sempre presente e por ser sempre essencial nos momentos difíceis. 
Mas especialmente, à minha Mãe por todo o amor e dedicação, por fazer o possível e o 
impossível por mim, por ser o meu exemplo de vida e por me permitir chegar até aqui, se não 
fosse por ela não estaria hoje a concluir esta etapa da minha vida. 
E por último, ao Diogo por tudo o que nos trouxe até aqui, mas especialmente pelo 
último ano que o passou ao meu lado, por tê-lo partilhado comigo, pela infinita paciência que 
teve para me aturar, que nem sempre foi fácil mas sobretudo pela peça essencial que é na 
minha vida para me ajudar a nunca desistir. Obrigado, és o melhor do mundo. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
   
  2
0
1
5
   
   
   
  I
d
en
ti
fi
ca
ti
o
n
 o
f 
b
io
m
ar
k
er
s 
fo
r 
Sc
h
iz
o
p
h
re
n
ia
   
   
 V
an
es
sa
 S
. S
. V
en
tu
ra
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“The only way to do great work is to love what you do” 
Steve Jobs  
Abstract 
Schizophrenia is a severe and chronic mental disorder that leads to loss of contact with 
reality. The treatment is based on the continuous administration of drugs in order to reduce 
the risk of new episodes. Being a brain pathology, the goal of the present work is the 
identification, in the prefrontal cortex, of molecules that may be potential biomarkers, which 
would be very helpful in the treatment of schizophrenia. 
Prefrontal cortex samples from 16 mice (4 of control, 4 administered with haloperidol, 
4 with citalopram and 4 with clozapine) were fractionated in two parts: soluble and 
membrane. Each one was further separated in proteins and metabolites. The membrane 
metabolites samples (studied in the present work) were prepared and analyzed resorting to 
HPLC-MS in reversed phase. Data treatment was made resorting to Principal Component 
Analysis, which allowed the direct visualization of data structure and also provided the 
relative positioning of the samples. The most discriminating peaks and a potential biomarker 
of schizophrenia were identified. 
 
  
Resumo 
Considerada como uma das doenças mais incapacitantes, a esquizofrenia caracteriza-
se como uma perturbação mental grave e crónica que leva à perda de contacto com a 
realidade. A doença apresenta vários sintomas, que dependem da fase da doença. O 
tratamento farmacológico é administrado continuamente de forma a reduzir o risco de novos 
episódios. Uma vez que a manifestação da patologia ocorre a nível cerebral, pretende-se com 
este trabalho identificar, em amostras de córtex pré-frontal, moléculas que possam ser 
reconhecidas como possíveis biomarcadores. Esta identificação seria certamente um forte 
contributo para o tratamento clínico da esquizofrenia. 
Amostras de córtex provenientes de 16 ratos (4 controlo, 4 administrados com 
haloperidol, 4 com citalopram e 4 com clozapina) foram fraccionadas em duas partes: solúvel 
e membranar. Cada uma destas foi depois separada em proteínas e metabolitos. As amostras 
de metabolitos de fase membranar (estudados no presente trabalho) foram preparadas e 
analisadas por HPLC em fase reversa acoplada a espectrometria de massa. 
A simplificação dos dados recolhidos foi efectuada recorrendo a métodos 
quimiométricos clássicos, nomeadamente a análise de componentes principais, que permitiu 
a visualização da estrutura dos dados e do posicionamento relativo das amostras. Foram 
identificados, em cada caso, os picos mais discriminantes, o que permitiu a identificação de 
um possível biomarcador para a esquizofrenia.   
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1. Introduction 
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1.1. Schizophrenia 
In 1911 Eugen Bleuler introduced the term “schizophrenia” as a description of this 
mental illness replacing Kraepelin’s term dementia praecox [1]. Since its demarcation and 
labeling as dementia praecox by Kraepelin (1887) and schizophrenia by Eugen Bleuler (1911), 
both definitions and scope have varied [2]. The process of splitting in schizophrenia according 
to Bleuler is the same as splitting of psychic connections in hysteria that in an extreme version 
can lead to the emergence of alter personalities and typical amnesia. In his Textbook of 
psychiatry he wrote (Bleuler, 1924): ‘‘It is not alone in hysteria that one finds an arrangement 
of different personalities one succeeding the other. Through similar mechanism schizophrenia 
produces different personalities existing side by side.’’ [1]. 
Schizophrenia (SCZ) is a complex psychiatric disorder with a heterogeneous clinical 
phenotype [3] which affects about 1% of the population and the understanding of its etiology 
remains incomplete [4]. It is characterized by an admixture of positive, negative, cognitive, 
mood, and motor symptoms whose severity varies across patients and through the course of 
the illness [2]. Presently, SCZ is not considered a single disorder but a group of conditions with 
manifestations common to other psychiatric and non-psychiatric disorders [4]. This disease is 
caused by the additive and interactive effects of genetic and non-genetic factors. Several 
genes have been identified as affecting brain development, plasticity  and  function,  which  
may  increase  vulnerability  to  environmental stressors  such  as  social  adversity  and  illicit  
drug  abuse.  
Antipsychotic (AP) medication is the mainstay of pharmacological treatment [5]. The 
current medical treatment of SCZ consists of drugs acting at multiple receptors, but how the 
modulation of each of these receptor targets contributes to the anti-psychotic effects is still 
poorly understood [6]. Currently, available AP drugs modify neurotransmission primarily in 
dopaminergic pathways. The long-term effectiveness of antipsychotics is limited by a 
combination of inadequate efficacy and poor tolerability [5]. 
For clinical purposes, a biomarker1 which might be detected by non-invasive methods 
would be desirable. To this end, several authors have identified possible biomarkers from 
                                                          
1
 A  ‘biomarker’ is  a  biologic  characteristic  objectively  measured  and  evaluated  as an indicator  of  normal  or  pathogenic  processes;  or  
of  response to  a  treatment  or  challenge  (Group,  2001).   
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peripheral blood, including neurotransmitter metabolite levels, stress hormones, markers of 
immune response and fatty acids [7]. 
Drug discovery for SCZ is hampered by poor success rates and the lack of success is 
mainly due to the complexity of the disease characterized by a diverse symptomatology that is 
impossible to treat with a targeted approach. The available agents are efficient for psychosis 
but do not adequately address other core domains of schizophrenia psychopathology, namely 
negative symptoms and cognitive impairment. To proceed in the research, the industry has 
followed new paths and applies new methods to discover innovative medicines for SCZ. 
Undoubtedly, the discovery and development of novel anti-schizophrenic drugs will benefit 
from the study of the effects on biomarkers and from the correlation between these effects 
and the changes in patients behavior [6]. 
Schizophrenia is one of most debilitating mental illnesses with chronic psychotic 
symptoms and presents a wide range of symptoms affecting most of the domains of brain 
function [3, 8]. Core symptoms of schizophrenia were traditionally divided into two groups: 
positive symptoms and negative symptoms [3].Positive symptoms refers to a cluster of 
symptoms that are abnormal by their presence [8]. These involve impaired reality testing and 
include delusions, hallucinations, and other reality distortions. Several kinds of delusions can 
occur and they can have varying degrees of persistence and systematization, and influence 
the individual's functioning to different extents. Negative symptoms reflect the absence of 
certain normal behaviors and emotions; they include flat affect, apathetic social withdrawal 
and poverty of speech. Negative symptoms involve a blunting or loss of a range of affective 
and cognitive functions. These include impairments in affective experience and expression, 
abulia (loss of motivation), alogia (poverty of speech), anhedonia (inability to experience 
pleasure), avolition (lack of initiative), apathy (lack of interest), and reduced social drive [2].  
These categories can be complemented with an additional group of cognitive 
dysfunction that include symptoms such as impaired attention, information processing, 
learning and memory [3]. 
The Course of SCZ 
The course of schizophrenia can be divided into premorbid, prodromal, first-episode, 
and chronic phases [9]. The course of SCZ is typically characterized by psychotic exacerbations 
or relapses alternating with periods of partial remissions [3]. In premorbid phase patients 
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often have a subtle and nonspecific cognitive, motor and/or social dysfunction [5]. In 
prodromal phase they have a gradual onset of symptoms, misperceptions, over-valued  
beliefs, ideas of reference, prior to the onset of psychotic symptoms [9]. The first psychotic 
episode indicates the formal beginning of SCZ, and finally, there is a stable phase, when 
psychotic symptoms are less prominent, and negative symptoms and cognitive deficits more 
predominant [2]. 
 
1.1.1. Epidemiology and Pathophysiology 
The World Health Organization (WHO) consider SCZ as the seventh greatest cause of 
disability worldwide being related both to genetic risk factors and environmental ones [5, 8, 
10]. 
This disease does not affect only mental health. Patients with a diagnosis of SCZ die in 
average 12–15 years before the average population, and this difference have increased in 
recent decades [11]. Although variable degrees of recovery occur [12], complete cure is 
unusual and in average an affected person lives with SCZ approximately 30 years [13]. The 
annual incidence of this disorder is 1–7/10,000 worldwide, being 2–6/10,000 in Europe, with 
an individual risk is 0.36–1.87% [5, 8]. Some deaths are suicides, but the main reasons for 
mortality are physical causes, resulting from decreased access to medical care and increased 
frequency of routine risk factors, such as poor diet, little exercise, obesity, and smoking [11]. 
According to current knowledge, SCZ is a complex disease caused by multiple etiological 
factors like urbanicity, male gender and environmental factors such as community demands. 
The available resources and treatment significantly alter the course of the disease and 
provides compelling evidence supporting a role for social factors in its etiology; the specific 
risk mediating factor social or biological, however, remains to be elucidated [7, 13]. 
The pathogenesis of this illness is still largely unknown [7] and in the absence of a 
biological marker, the current diagnosis of SCZ and its treatment are mainly based on clinical 
questionnaires. Thus, it is not surprising that the response rate is unsatisfactory, in particular 
after multiple treatment attempts, and relapse is common for patients who discontinue 
medication [14].  
 The US-based 4th Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV) [15] 
and the 10th International Classification of Diseases (ICD-10) [16] are currently used to 
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diagnose SCZ. As referred above, the absence of an objective test for diagnosis has boosted 
the studies aiming at the identification of a biomarker that could be detected by non-invasive 
methods [5, 7, 17]. The potential utility of neuronal biomarkers such as neurotransmitter 
metabolite levels, stress hormones, markers of immune response and fatty acids is a topic 
that, recently, has attracted much interest [17-20].  
Currently, resorting to modern neuroimaging techniques, the study of the 
pathophysiological changes of SCZ is possible [5]. Structural brain imaging has shown a subtle, 
almost universal, decrease in grey matter, enlargement of ventricles, and focal alteration of 
white matter tracts [21-23], indicating that the hippocampus [24] and cortex [25] have a 
central role in the neuropathology and pathophysiology of SCZ. These observations support 
the idea that SCZ is associated with altered brain function. Altered neurotransmission is a key 
pathophysiological mechanism underlying the expression of schizophrenic symptoms and for 
decades, pathophysiological studies relating to schizophrenia were focused on disturbances of 
dopaminergic and glutamatergic though GABAergic, serotonergic, cholinergic and opioid 
transmitter systems have also been implicated [4, 8]. 
Dopamin hypothesis 
Abnormalities in dopaminergic systems are thought to be the bases for some 
neuropsychiatric disorders such as Parkinson’s disease and SCZ [26]. Dopamine is a 
catecholamine (CA) neurotransmitter that regulates functional network activities in various 
regions of the brain [27] and participates in the regulation of motor functions and of cognitive 
processes such as learning and memory [26]. 
GABAergic and Glutamatergic hypothesis 
 In 2009, Howes and Kapur postulated a version of DA hypothesis that focuses on the 
modulating effect of other neurotransmitters such as glutamate and gamma-aminobutyric 
acid (GABA) in the DA system [7]. The contribution of this acid, GABA, in cognitive function has 
received increasing attention in diseases such as SCZ [28-30]. 
Postmortem studies revealed the existence of a relationship between cognition and 
some alterations in GABA receptors. The inhibition of GABAergic neurotransmission plays a 
major source since it mediates several cognitive operations including information processing 
and memory [31].  
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The glutamate hypothesis in SCZ focuses on disturbances in brain glutamatergic 
pathways and impairment in signaling at glutamate receptors [32, 33]. It is an alternative or 
complementary theory to the dopamine hypothesis [34, 35]. 
Serotonin hypothesis 
According to Allman, the serotonergic participates in our emotions being associated 
with the regulation of anxiety, stress, and mood [36, 37]. 
Cholinergic hypothesis 
The role of the cholinergic system in SCZ remains controversial. Several researches 
revealed that pharmacological manipulation in cholinergic system allow to observe changes in 
SCZ, suggesting that it has influence on positive and negative symptoms [38].  
 
1.2. Therapeutic approaches in schizophrenia 
There are a wide range of available antipsychotic drugs that differ in chemical structure 
and receptor profile. In spite of that, all AP drugs modify dopaminergic transmission in the 
brain [39]. These drugs are effective for delusions and hallucinations but less efficient for 
disabling cognitive and motivational impairments [5], however their main benefit is to reduce 
the risk of "relapse" [9].  
Antipsychotic drugs can be divided into two categories, the first and second generation 
of AP. The First–Generation antipsychotics (FGAs), also called typical or conventional AP, 
started with the introduction of Chlorpromazine, in 1950s and prompted the development of 
several other antipsychotic drugs. These opened the new era of modern AP [40]. In treatment 
of SCZ, these drugs are used as a primary choice and many studies have concluded that they 
can be applied to treat patients with psychotic symptoms [41]. So far, the typical AP 
significantly decrease the positive symptoms, 60-70% [39]. The most known example of FGAs 
is Haloperidol (HA) which is widely used in treatment of SCZ and also in the treatment of 
delirium and other situations that include the control of the symptoms of acute psychosis, 
among others [42-44]. 
Haloperidol was firstly synthesized in 1958, but it was only introduced in the market in 
1967, in the United States [43]. Initially the drug was used in the field of anesthesia and its 
 7 
 
introduction as AP only came after the research of Ayd and Settle [45], in which the beneficial 
effects on hallucinations, delusions, aggression, impulsiveness and states of excitement was 
demonstrated. This AP is still known by its high capacity of dopamine blockade in comparison 
with other existing antipsychotics and due to its smaller doses in comparison with other 
drugs. According to these features it is considered as one of the most successful drugs to 
achieve antipsychotic effects [46].  
Another type of AP is the second-generation (SGAs) also called atypical drugs. The use of 
this AP drugs started in 1970s, with the development of Clozapine (CL), and has increased 
recently [47, 48]. In spite of some controversy in the topic, some authors argued that the 
SGAs have a higher efficiency, with fewer side effects and less negative symptoms than de 
FGAs [49-51]. 
Clozapine was, as stated above, the first atypical drug or SGAs to be implemented in 
clinical practice [42]. Its implementation occurred almost half a century ago, and in spite of 
some mishaps [52], this drug return to market, in 1980, and revolutionized the world of 
antipsychotics. In 1990 Kane and his colleagues compared the effect of CL and 
chlorpromazine, and concluded that 70% of the patients responded positively to the 
treatment with CL and only 5% to the chlorpromazine. After this reference study, it was 
recognized that clozapine had a different spectrum profile of therapeutic effects that have not 
been recognized in other antipsychotics. Since then, other new second-generation 
antipsychotics, such as Olanzapine, Quetiapine and Risperidone, for example, have been 
developed [53-56]. The success of CL was mainly due to the improvements in both positive 
and negative symptoms of SCZ. Unlike other drugs, the use of CL is not associated with the risk 
of movement disorders [47]. It also features a strong affinity with dopamine and serotonin 
systems showing a locking effect [42] which contributes to its efficacy and increased 
therapeutic action [55]. 
Another treatment option in SCZ is the use of antidepressants (AD). Presently, the use of 
AD is the most used treatment, with almost 233 million prescriptions in 2007 [57]. 
Until the 1970s, AD were divided into two categories: tricyclic antidepressants and 
monoamine oxidase inhibitors [58]. Currently the various classes of antidepressants 
commonly used are the selective serotonin reuptake inhibitors (SSRIs), selective serotonin and 
norepinephrine reuptake inhibitors (SNRIs) and atypical antidepressants. Selective serotonin 
reuptake inhibitors are the most frequently used for the treatment of severe depression and 
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obsessive compulsive disorder, among others. The SNRIs behave similarly to SSRIs. Both 
groups are considered agents usually well tolerated and safe. They are also effective in anxiety 
disorders and depression but they are not yet widely studied as the SSRIs [41]. 
One of the most commonly used antidepressants and SSRIs is Citalopram (CI) which is 
considered the more selective [59]. Although the drug is commercialized as a racemic mixture 
of (S) - (+) and (R) - (-), the SSRI activity resides essentially in the S- form being the R-
enantiomer practically devoid of inhibitory potency of serotonin reuptake. This discovery led 
to the development of the drug as a single enantiomer, escitalopram (S-citalopram), which 
has a faster effect and effectiveness than the racemic mixture [60]. Citalopram is mostly used 
in the treatment of psychiatric disorders, but it is also suited to treat anxiety or eating 
disorders [57].  
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 2. Technical Strategies  
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2.1. Metabolomic Studies 
Metabolomics is the study of metabolism at the global level and its main goal is the 
identification and quantification of metabolites (dynamic set of all small molecules (<1500 
Da)) present in organisms or biological samples. The concept of metabolomics covers the 
global analysis of all metabolites in a sample. In this project, pre-frontal cortex samples will be 
used, and the analysis will be focused on the metabolomic responses to HA, CL and CI drugs. 
These studies aim at helping in diagnose of diseases [61-64]. Currently, there are two 
complementary approaches for metabolomic studies: metabolomic profile and metabolomic 
fingerprinting [65]. The central objective of the first is the analysis of a group of metabolites 
that are related to a specific metabolomic pathway. The results of these approaches are 
quantitative and ideally independent of the technology used for data acquisition, and the data 
can be used to build or enlarge databases. The second approach does not intend to identify 
metabolites, but rather it compares patterns or ‘fingerprints’ of metabolites that change in 
response to disease [66]. Both strategies can be used in the search for new biomarkers as 
indicators of disease traits (or markers of risk), disease states, or illness progression [63, 66]. 
In SCZ, the identification of biomarkers is particularly important to improve diagnostics 
and therapy since there are no validated biomarkers [67]. Only in a few studies the 
metabolomics profile of SCZ was assessed. However, none of these succeed in validating a 
biomarker [61, 64, 68, 69].  
Although metabolomics studies often rely on nuclear magnetic resonance (NMR) and 
mass spectrometry (MS) data, the latter is more often used, due to its higher sensitivity [70] 
and higher selectivity [62]. The coupling of MS with liquid chromatography (LC-MS) and in 
particular with high performance liquid chromatography has proven to be very successful in 
this area. HPLC separation is the most versatile method, because it allows the separation of 
compounds with a wide range of polarity [62]. 
Mass spectrometry uses versatile mass analyzers operating in tandem or hybrid 
configuration to more effectively perform the identification of metabolites by acquiring 
MS/MS spectra. The fragmentation of ions is made through collisional induced dissociation 
(CID) in a collision cell after precursor isolation in the quadrupole TOF (Q-TOF) instrument. The 
success of the separation also depends on the right choice of the HPLC columns. For semi-
polar compounds the choice generally relies on the use of reversed phase C18 
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chromatography (RPC), while for polar compounds the hydrophilic interaction liquid 
chromatography (HILIC), that uses generally polar columns is the preferred one[62]. In what 
concerns sample preparation, solid phase extraction (SPE) has become one of the most 
important techniques in order to clean the samples [66]. 
 
2.2. Liquid Chromatography – Mass Spectrometry 
Liquid chromatography coupled to mass spectrometry is a powerful analytical technique 
that gives qualitative and quantitative information about the samples to be analyzed. It is 
widely use in various fields including proteomics and metabolomics. This technique combines 
the physical separation capabilities of liquid chromatography (or HPLC) with the mass analysis 
capabilities of MS. The coupling with MS provides a better solution for the analysis of complex 
mixtures allowing, for example, the separation of isomers [71, 72].  
 
2.2.1. High performance liquid chromatography 
 Liquid chromatography is an analytical technique that allows the separation of the 
components of a mixture based on their relative affinities with the stationary and mobile 
phases. In a simplified form, this technique involves the introduction of the sample into the 
column in which the compounds are distributed according to their affinity with the stationary 
phase [73]. The chromatographic separation is based on the different interactions occurring 
between the components of the mixture and the stationary and mobile phases. HPLC 
operates in two main modes, the normal phase chromatography (NPC) and reverse phase 
chromatography (RPC). In NPC, the least polar compounds elute first and more polar 
compounds elute last. Reversed-phase chromatography employs a polar mobile phase, and as 
a result the less polar molecules in the mobile phase tend to adsorb to the stationary phase, 
while polar molecules in the mobile phase will pass through the column and are eluted first.  
The mobile phase can also be of intermediate polarity by using a mixture of organic solvent 
with an extra level of water (e.g. ACN). A common example the stationary phase is RMe2SiCl, 
where R is an alkyl chain such as C18H37 or C8H17. In this case the retention time is longer for 
non-polar molecules, while the polar ones are eluted more quickly [73].  
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Another method, less known is the hydrophilic interaction liquid chromatography 
(HILIC). It allows an efficient separation of smaller polar compounds in polar stationary 
phases. Several studies show that the HILIC mode is an "evolution" of NPC, however their 
mechanism of separation is more complicated. HILIC uses polar stationary phases with 
reversed-phase type eluents. 
It is commonly believed that in HILIC, the mobile phase forms a water-rich layer on the 
surface of the polar stationary phase vs. the water-deficient mobile phase, creating a 
liquid/liquid extraction system. The analyte is distributed between these two layers. The more 
polar compounds will have a stronger interaction with the stationary aqueous layer than the 
less polar compounds. Thus, a separation based on compounds polarity and degree of 
solvation takes place. This mode shows some differences from the RPC, like the elution order 
of compounds that acts in the opposite direction, that is, from the less polar to more polar 
[74]. 
Mass Spectrometry  
In mass spectrometry the sample components are ionized resulting in charged 
molecules or molecule fragments and their mass-to-charge (m/z) ratios are measured. In LC-
MS, the MS works as a high sensitive and sophisticated detector [75]. In Figure 1 the main 
components of a mass spectrometer are schematically represented. These include sample 
introduction device, ionization source where the formation of gaseous ions occurs, mass 
analyzer that separates the ions formed according to their m/z, detection and quantification 
of ions and data acquisition [76]. 
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Figure 1 – Schematic representation of the components of a Mass Spectrometer. Adapted from [76] 
 
Ion Source 
The ion source is responsible for the ionization of the analyte into molecular ions. This 
step can occur by two different modes: (i) the hard mode, using ionization energy sources 
resulting in a high degree of fragmentation; (ii) the soft mode in which a low degree of 
fragmentation is obtained [75]. 
 The most common LC-MS ionization sources are electrospray ionization (ESI), 
atmospheric-pressure chemical ionization (APCI) and atmospheric pressure photoionization 
(APPI). Over the last decade, electrospray ionization has become a very powerful technique 
capable of analyzing both small and large molecules of various polarities in complex biological 
samples [77]. It operates on the soft mode at atmospheric pressure and at room temperature, 
either in positive and negative ionization modes. Initially, the sample is nebulized by a N2 flow 
and subjected to a 3-5 kV voltage to create an electrically charged spray of droplets. The 
subsequent evaporation of the solvent from the charged droplet makes it unstable upon 
reaching its Rayleigh limit. At that point, the droplet deforms as the electrostatic repulsion 
overcomes the surface tension holding the droplet together. The droplet undergoes Coulomb 
fission, and gives rise to many smaller, more stable droplets. The new droplets undergo 
desolvation and subsequently further Coulomb fissions (Figure 2) [78].  
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Figure 2 – Schematic representation of the electrospray ionization process. Adapted from [79]. 
 
 Electrospray is considered a soft ionization technique, since fragmentation is low. This 
can be an advantage since the molecular ion is always observed, however little structural 
information can be gained from the simple mass spectrum obtained. This disadvantage can be 
overcome by coupling ESI with tandem MS (ESI-MS/MS), in which the fragmented ions after 
passing through the collision cell (CID) may undergo to analysis via a second analyser, the 
tandem mass spectrometer (MS/MS or MS2)  [77].  
 
Mass Analyzer 
 All mass spectrometers combine ion formation, mass analysis and ion detection. Mass 
analyzers are used to separate ions according to their m/z ratio. Each mass analyzer has its 
own special characteristic and applications and its own benefits and limitations. Some mass 
analyzers are quadrupole (Q), quadrupole ion trap (QIT), linear ion trap (LIT), orbitrap, time-
of-flight (TOF), ion cyclotron resonance (ICR) and magnetic/sector (less used). The 
performance of each analyzer takes into account aspects such as the speed of analysis, 
transmission, accuracy and mass resolution [80]. 
 The quadrupoles are the most used mass analyzers [81]. They consist of four cylindrical 
electrodes (rods), parallel to each other (see Figure 3). In a quadrupole mass spectrometer, 
the quadrupole is the component of the instrument responsible for filtering sample ions 
based on their m/z ratio. Ions are separated in a quadrupole based on the stability of their 
trajectories in the oscillating electric fields that are applied to the electrodes.  
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Figure 3 - Schematic representation of a quadrupole mass analyser. Adapted from [82] 
 
Each opposing electrode pair is connected electrically and a radiofrequency voltage is applied 
between each pair of electrodes. A direct current voltage is then superimposed on the 
radiofrequency voltage. The ions travel down the quadrupole between the electrodes and 
only ions of a certain m/z ratio will reach the detector for a given ratio of voltages. Others, 
have unstable trajectories and will collide with the electrodes, being unable to reach the 
detector since the amplitude of oscillations became infinitive (see Figure 4). This allows 
scanning for a range of m/z values by continuously varying the applied voltage [75, 82]. 
 
 
Figure 4 – Scheme of paths capable of acquiring from the filter action of the quadrupole. The blue circles represents m/z 
values with unstable trajectories that collide with the electrodes, being unable to reach the detector; the other ions represent 
stable trajectories thus being able to reach the detector. Adapted from [83] 
 
To solve some specific problems, the MS/MS is a good solution and the most used in LC-
MS, especially in biological compounds. This tool offers a faster screening of the sample, and 
offers a much higher sensibility [84]. In a MS/MS instrument, the system can be constituted by 
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three quadrupoles. The first and the third act as mass filters and the middle quadrupole (q2) is 
employed as a collision cell (Figure 5) [78]. 
 
 
Figure 5 – A triple quadrupole mass spectrometer scheme. Q1 and Q3 act as mass filters and can be independently fixed, 
scanned or stepped; q2 is a collision cell that contains a low pressure inert gas. Adapted from [85]. 
 
 The evolution of MS/MS leads to spectrometers in which the final quadrupole is 
replaced by a time-of-flight device as the second mass selection stage originating a hybrid 
instrument - Quadrupole time of flight (Q-TOF). This has  the advantage of having a higher 
resolution. In TOF, the ions are accelerated by and electric field to the same kinetic energy 
and the velocity of the ion depends on their m/z ratio. The basic function of TOF is to measure 
the velocity, from which the m/z ratio can be determined. Therefore, TOF accelerate the ions 
according to their kinetic energy allowing the smaller ions to reach the detector faster [75, 
82].  
 
Figure 6 – Electrospray tandem mass spectrometer with TOF. Adapted from [86] 
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2.2.2. HPLC-MS data processing 
In recent years, metabolomics has grown as an important tool for the analysis of 
biological systems and, particularly, in the diagnosis of diseases such as SCZ. The work done in 
this field produces a huge amount of data and therefore the identification and quantification 
of the metabolites requires a very careful and thorough manipulation of the dataset collected. 
The HPLC-MS data processing is an area still in development [87]. Data treatment can be 
divided in two steps: data processing and data analysis. The first consists essentially in 
transforming raw data into an accessible format while the latter consist in the interpretation 
of the information through multivariate analysis [88, 89].  
In this project the main steps of data processing were peak detection (finds the peaks); 
alignment (data processing step specific to profiling experiments) and finally normalization (to 
reduce systematic errors by adjusting the intensities within each sample run) [87].  
2.3. Data Analysis  
The type of study performed in this project produce a huge amount of data being often 
difficult to choose the most relevant information. Multivariate data analysis and 
chemometrics methods have provided powerful tools for metabolomics data processing [90]. 
Chemometrics was introduced in 1972 by Svante Wold and Bruce R. Kowalski and includes a 
variety of mathematical and statistical methods to design and select procedures or 
experiments to simplify and characterize the system under study. The evaluation and 
interpretation of the relevant information aims at identifying the underlying patterns, and 
expressing the data in such a way as to highlight their similarities and differences. To this end 
different methods can be applied, such as cluster analysis and principal component analysis, 
among many others.  
 
2.3.1. Principal Components Analysis  
Principal Component Analysis (PCA) is an unsupervised technique that aims to reduce 
the dimensions of the dataset with minimal loss of information [91, 92]. PCA computes a 
compact and optimal description of the dataset, providing a roadmap to lay out a complex 
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dataset to a lower dimension and reveal the hidden, simplified structure that often is 
underlying. 
PCA allows essentially to (i) extract the key information acquired from the data set, (ii) 
reduce the data dimensionality, keeping the most relevant information, (iii) establish the 
relationship between observations and variables, (iv) visualize and interpret the target 
system. In simple terms, the PCA procedure involves an orthogonal linear transformation that 
transforms the data into a new coordinate system in which the greatest variance lies on the 
first coordinate (called the first principal component), the second greatest variance on the 
second coordinate, and so on (see Figure 8).  
 
 
Figure 7 – Schematic representation of the PCA procedure. The greatest variance of the data lies on the first principal 
component. 
 
These new variables called Principal Components (PC's) are obtained by linear 
combinations of the original variables, and these should gather most of the variability of the 
original dataset. The coordinates of the data in the new reference system are called “scores”, 
while the coefficient of the linear combination that describes each principal component (PC), 
or the weights of the original variables in each PC are called “loadings”. The principal 
components can be ordered by descending order of their variance. The PC´s with the higher 
variance are the ones that describe more properly the system. The most influential variables 
in the system are highlighted, and the most relevant factors may be identified. PCA is based 
on the assumption that most of the information about the structure of the data is contained 
in the directions along which the variations are the largest [91, 92]. Specifically, the original 
multi-dimensional space, defined by the parameters characterizing each sample, is contracted 
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into a few descriptive dimensions, which represent the main variation in the data. Each 
principal component can be displayed graphically and analyzed separately, and its meaning 
may often be interpreted according to simple descriptors. Essentially, the procedure is carried 
out by a linear transformation of the m analytical parameters xi into a new set, the principal 
components ui 
ui = wi1x1 + wi2x2 + · · · + wimxm    (1) 
where wi1. . .wim are the loadings, i.e. the weights of the observed parameters in the linear 
combination. In PCA, the original matrix X (n × m), in which n rows correspond to n samples 
and m columns correspond to the number of variables, is decomposed as a product of two 
matrices, 
X = SWT          (2) 
in which S (n × m) is the matrix of the scores, i.e. the coordinates of the samples in the 
principal components, and W (m × m) is the loadings matrix. Since the first principal 
components retain most of the variance, several variables can be summarized by a few 
components and a graphical representation of the first two or three PCs enables the 
visualization of most relevant information contained in the data [93].  
The principal components are not correlated with each other and altogether explain the 
total variance of the data. The transformation matrix W whose elements are the loadings wij 
and the vector , whose components correspond to the recovered variance i in each i
th 
principal component, can be obtained via a singular value decomposition 
CxW = W       (3) 
where Cx corresponds to the variance/covariance matrix of the original data. Also, ∑ 𝑖
𝑚
𝑖  gives 
the total variance of the data. Frequently, Cx is replaced by the correlation matrix, in a 
normalized approach. In this case, ∑ 𝑖
𝑚
𝑖 = 𝑚. 
A fundamental step to determine the number of significant PCs is the extraction of 
eigenvalues and eigenvectors. 
 The selection of the most relevant first p principal components can be done using 
different criteria [93]. The most common one is the Pearson criterion, which can be used in 
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conjunction with both the variance/covariance matrix and the correlation matrix. The value p 
is selected as the minimum integer that warrants 
∑ 𝑖
𝑝
𝑖=1
∑ 𝑖
𝑚
𝑖=1
⁄  0.8      (4) 
If the correlation matrix is used, the most common criteria correspond to retain the p 
components for which  1. The λ≥1 rule, also known as Kaiser criterion, is selected when the 
correlation matrix is used. This rule takes into account all components with eigenvalues 
greater than one.  
A more robust criteria is the scree plot. This representation displays the eigenvalues as a 
function of the corresponding principal components, as shown in Figure 8.  According to this 
criteria the relevant principal components are those that markedly standout from the 
remaining in terms of variance. 
 
 
Figure 8 - Scree Plot example suggesting 1 PC solution.  
 
In the present work, PCA is used to rationalize the information related to the 
identification of SCZ biomarkers. Specifically, the main focus is the study and identification of 
metabolites that may be altered by the effect of three different drugs, haloperidol, citalopram 
and clozapine. The data were collected from pre-frontal cortex samples of mice, resorting to 
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HPLC-MS/MS analysis. Efforts were made to establish correspondence between the most 
relevant metabolites and molecules available databases. 
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3. Materials and Methods 
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3.1. Drug administration and extraction of pre-frontal cortex 
in mice 
Young black male C57BL/6J mice were purchased from Charles River, Laboratories 
International, Inc. (Spain) and kindly prepared in Dra. Graça Baltazar’s lab with the help of 
Sandra Rocha (University of Beira Interior, Covilhã). Mice were divided into four groups, of 6 
animals each. Each animal weighed around 20-25 g with access to food and water ad libitum. 
Animals were chronically treated for four weeks.  The  animals  were  injected,  via  
intraperitoneal  with  clozapine,  citalopram  or  haloperidol  at  a  dose  of  20  mg/Kg,  10  
mg/Kg  and  1  mg/Kg,  respectively. All drugs were dissolved by diluting on a stock solution of 
0.13% HCl 5M with 0.9% NaCl. An additional group was treated only with vehicle (saline 
solution) being considered the control group.  The age of animals at the beginning of the 
habituation phase was 10 weeks and mice were injected daily for 30 days. After drug 
administration, the animals were weighed and anesthetized with a mixture of ketamine (100 
mg/Kg) and xylazine (10 mg/Kg) 24 hours after the final injection. Finally, they were sacrificed 
and their brains removed and dissected bilaterally and the prefrontal cortex was collected. 
TEAB 0.5 M (triethylammonium bicarbonate buffer) with phosphatases and proteases 
inhibitors (Roche) was added to each tube. All samples were stored at -80˚C until use. These 
samples were already used by Susana Costa Saraiva master thesis for performance an analysis 
of PFC proteome. The metabolites were stored at -80˚C until now for their use in this the 
project. 
3.2. Internal Standard Tests 
Internal standard (I.S.) is a necessary step for quantification in HPLC-MS since it allows 
to see if any alteration occurs during the execution of the procedure/sample analysis. A 
mixture of 56 compounds (available in the laboratory) was prepared in a solution of 2% 
acetonitrile (ACN) and 1% formic acid (FA) to a final concentration of 10 µM. The mixture was 
then subject to C18 tips process (OMIX TIP C18 100 µl, Varian), which includes: 1) conditioning 
with 50% ACN solution; 2) equilibrate with 2% ACN + 1% FA solution; 3) sample; 4) rinse with 
2% ACN + 1% FA solution; 5) elution with 70% ACN + 0.1% FA solution;  6) 100% ACN + 0.1% 
FA solution; 
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The two first steps were performed to prepare the tip for the sample. After that, the 
sample was added to C18 tip passed 5x, the next step, the rinse was performed by passing 1x 
(100 µl) 2% ACN + 1% FA solution and the elution was made by passing 4x (100 µl) of 70% ACN 
+ 0.1% FA solution. This elution step is the most important one because it will show which 
compounds have affinity with C18 and were not wasted in the first two steps. This 
requirement is essential for being considered as internal standard. An extra step was 
performed by passing 4x (100 µl) 100% ACN + 0.1% FA solution for evaluation of the efficiency 
of SPE. The first two fractions were discarded, and the collected fractions were denoted as F1 
(step 3), F2 (Step 4), F3 (step 5) and F4 (step 6). Samples were then evaporated and 
ressuspended in a 2% ACN + 0.1% FA solution, followed by sonication at 20% of amplitude for 
2 minutes (1 second on 1 second off cycle) and transferred to vials for LC-MS analysis. 
 
3.3. Metabolite Extraction 
Metabolite extraction was performed by the membrane protein enrichment protocol. 
The tissue was removed from the storage at -80˚C and thawed at room temperature. Samples 
were transferred to centrifuge tubes and 1 mL of Tris 0.05 M 
(tris(hydroxymethyl)aminomethane) pH=7,4 with phosphatases and proteases inhibitors 
added. Subsequently, tissues were homogenized with ultrasonication (Vibra Cell 130 watts, 
Sonics) with the 2 mm probe for 30 seconds at 40% amplitude with 1 second cycles and for 15 
seconds at 50% with 1 second cycles and centrifuged (Centrifuge 5417R, Eppendorf) at 
5,000×g for 5 minutes at 4˚C. Supernatants were stored in a new microcentrifuge tube and 
500 µL of Tris 0.05 M with phosphatases and proteases inhibitors were added to the pellets. 
Supernatants were transferred to ultracentrifuge tubes and the pellets were kept at -80˚C. In 
the next step, an ultracentrifugation (OptimalTM L-100 XP, Beckman Coulter) at 144,000xg for 
1h at 4˚C was performed and the supernatant (soluble fraction, SF) was taken to a 
microcentrifuge tube. For the pellet (membrane fraction, MF) 500 µL of TEAB 0.5 M plus 500 
µL of water was added (because TEAB has 1M of concentration) and the pellet was dissolved 
using the sonicator with the 2 mm probe for 15 seconds at 40%, once, after this the pellet was 
unstacked from the ultracentrifuge tube and homogenized again, 30 seconds at 40% 
amplitude with 1 second cycles and 30 seconds at 50% amplitude with 1 second cycles, this 
step was repeated until total dissolution. The MF and SF were subjected to protein 
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precipitation with MeOH (Methanol) and 1:4 (sample: methanol) was added in each. Fractions 
were vortexed (IKA Vortex 4basic) between 10 to 15s and stored for 20min at -80˚C. To obtain 
proteins and metabolites, it was performed a new centrifugation (Centrifuge 5810 R, 
Eppendorf) at 3.220×g at 4˚C for 20min. Supernatants (metabolites of MF and SF) were 
removed and transferred to microcentrifuge tubes, and the pellets (proteins) were stored at -
80˚C. Supernatants were evaporated in the speedvac (Eppendorf, Concentrate plus) during 3h 
and 25min at 60˚C to perform a successful evaporation of all metabolites. When this was 
complete, the samples were resuspended and sonicated (Bioblock Scientific vibracell 75041) 
during 2min at 20% with 1 second cycles and subjected to vortex and centrifuge (Minispin 
plus, Eppendorf) with 14.100xg for 5 min. The pellets were stored and the supernatants were 
subjected to a solid-phase extraction protocol using C18 tips (OMIX TIP C18 of 100 µl from 
Varian) according to the process described above. Samples were evaporated during 1h and 
ressuspended with 30 µl of 2% ACN + 0.1% FA solution in each tube. After vortex, sonication 
and spin all the samples were transferred to vials for LC-ESI-QTOF-MS (Sciex) analysis. To 
optimize the protocol it was performed a set of different options with the internal standards 
mixtures. In Table 1 are summarized the four options that were considered for the addition of 
the internal standard. 
Table 1 – Options considered to perform the I.S. spike in membrane protein enrichment protocol. 
 
1
st
 2
st
 3
st
 4
st
 
Matrix ✔  ✔ ✔ ✔ 
I.S ●    
Ultracentrifugation ✔ ✔ ✔ ✔ 
I.S.  ●   
Protein Precipitation ✔ ✔ ✔ ✔ 
I.S.   ●  
C18 tips ✔ ✔ ✔ ✔ 
I.S.    ● 
LC-MS analysis ✔ ✔ ✔ ✔ 
 
3.4. Preparation of pre-frontal cortex samples 
The main focus of this project was to perform a metabolomic analysis with PFC samples. 
As previously mentioned, the metabolites of PFC obtained by Membrane protein enrichment 
protocol was already set, by Susana Saraiva masters’ thesis. The metabolites PFC samples are 
divided in two categories: membrane fraction (MF) – fraction that was analyzed in the present 
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project - and soluble fraction (SF).  Each category has 4 groups of samples, Control (CT), 
Haloperidol (HA), Citalopram (CI) and Clozapine (CL) and each group had 4 replicates.  
Table 2 – Description of the SF and MF  groups. 
Soluble Fraction Membrane fraction 
CT1 HA1 CI1 CL1 CT1 HA1 CI1 CL1 
CT2 HA2 CI2 CL2 CT2 HA2 CI2 CL2 
CT3 HA3 CI3 CL3 CT3 HA3 CI3 CL3 
CT4 HA4 CI4 CL4 CT4 HA4 CI4 CL4 
 
Samples were sonicated with 2min at 20% with 1 second cycles and ultra-sonicated 
(VWR Ultrasonic cleaner, USC-THP) with 3 min at 7 powers at 25˚C. The next step was to 
ressuspended the samples in 100 µl of 2% ACN + 1% FA in each. After that, they were divided 
and 50 µl were transferred to a new microcentrifuge tube and stored at -80˚C. Samples were 
identified according to the labels in table 2. 
The samples were subject to vortex, sonication and centrifugation and then subject to 
C18 tips. The C18 protocol was performed as described above and for that three solutions 
were necessary: a) 50% ACN, b) 2% ACN + 1% FA and c) 70% ACN + 0.1% FA and make the five 
first steps that were required in this process. Subsequently, the samples were evaporated 
during 1h and ressuspended with 30 µl of 2% ACN + 0.1% FA solution and I.S. solution 
(Sulfamethazine-D4). Samples were then subject to vortex, sonicator and spin, and finally 
transferred to vials for HPLC-MS/MS analysis. 
 
3.5. HPLC-MS/MS analysis  
Samples were analyzed on a NanoLC Ultra 2D separation system (Eksigent) coupled to 
an electrospray ionization source (DuoSpray™ Source, Sciex) operated in positive mode, and a 
Triple TOF™ 5600 System mass spectrometer (Sciex). Metabolites were separated into a Halo 
C18 column (0.3 x 150 mm, 2.7 μm, 90 Å, Eksigent) at 5 μL/min, with an acetonitrile gradient 
(2% to 61% ACN, for 42 minutes) in 0.1% FA. Using the same chromatographic conditions, 
mass spectrometer was programmed for two different forms of data acquisition: information 
dependent acquisition (IDA) and information independent acquisition SWATH analysis. For 
IDA, a full mass spectra (30-1250 m/z) was acquired, followed by 11 MS/MS of ions with +1 to 
+4 charges and one MS/MS was performed before adding those ions to the exclusion list for 
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15 seconds. For SWATH experiments, the mass spectrometer was operated in a looped 
product ion mode. The instrument was specifically tuned to allow a quadrupole resolution of 
50 m/z mass selection. Using an isolation width of 51 m/z (containing 1 m/z for the window 
overlap), a set of 17 overlapping windows was constructed covering the precursor mass range 
of 50–900 m/z. A 250 milliseconds survey scan (50-2000 m/z) was acquired at the beginning of 
each cycle and SWATH MS/MS spectra were collected from 50–1300 m/z for 120 milliseconds 
resulting in a cycle time of 2.34 seconds from the precursors ranging from 50 to 900 m/z. The 
collision energy for each window was determined according to the calculation for a charge 1+ 
ion centered upon the window with a collision energy spread of 15. The mass spectrometer 
was operated by Analyst® TF 1.6, Sciex. 
 
3.6. HPLC-MS data processing 
The characterization of biological samples generates a large amount of complex data 
which is difficult to describe and rationalize. Chemometrics provides useful tools to assist in 
the characterization of these systems. In this project different softwares were used: i) 
MarkerViewTM software (version 1.2.1.1, Sciex) for peak detection, peak alignment and PCA 
analysis; ii) MultiQuantTM 2.1.1 software (version 2.1.1742.0, Sciex, 2012) for peak integration; 
iii) Predictive analytics software and solutions (SPSS) (version 18, PASW Statistic 18, Release 
18.0.0) for Mann-Whitney significance test. An outlook of the data processing procedure is 
shown in Figure 9. 
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Figure 9 – Data processing workflow with the identification of the software used in each step. 
 
 In simple terms, the data files acquired by MS were directly imported to 
MarkerViewTM. For peak detection the following criteria were applied: a) retention times 
above 5 minutes; b) minimum spectral peak width of 0.02 Da (peaks narrower than this value 
are presumed to be noise); c) minimum retention time peak width of 4 scans; d) maximum 
retention time peak width of 10 scans (peaks wider than this value are assumed to be 
background ions). Data alignment was applied to compensate smaller variations in mass and 
retention times, to ensure that similar compounds in different samples are accurately 
compared. Additionally, retention time tolerance was set to 0.5 minutes, and mass tolerance 
set to 30.0 ppm. According to these criteria two or more peaks having the same m/z value 
were considered the same if the retention time did not exceeded 0.5 minutes. The same 
occurs when two or more peaks differ at the most in 30.0 ppm. Peak detection, alignment and 
normalization were carried out using Pareto2 scaling approach in MarkerView. Preliminary 
PCA´s were performed directly on the global set of normalized integrated peak areas. 
Subsequent PCA´s were performed on filtered data, obtained through significance tests 
including t-test (performed in an “noise reduction approach”) and  Mann-Whitney (using SPSS 
                                                          
2
 According to MarkerView software, in Pareto each peak is subtracted by the average and divided by the square 
root of the standard deviation. This is a good initial choice for MS data since it prevents intense peaks from 
completely dominating the PCA analysis, but also allows peaks with good signal/noise to have more importance. 
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software). Peak areas were calculated by MultiQuant, using normalized data with internal 
standard3. 
 
                                                          
3
 Internal standard used was Sulfamethazine-D4, a regular compound utilized in the laboratory. 
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4. Results and Discussion 
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4.1. Internal standards: preliminary tests  
Internal standard tests were performed testing a set of 56 different compounds (see 
Table 7 in supplementary material), which should satisfy the criteria of being similar to the 
analyte, have a similar retention time, be stable and not interfere with the sample matrix.  
The prepared samples were subjected to the same procedure of that of the pre-frontal 
cortex ones. Thus, C18 tips were used in order to remove interferences before the HPLC-
MS/MS analysis. Three different fractions were obtained through this process, the loading 
sample, the washed and the eluted fractions, being the latter the most interesting one.  
From the 56 compounds, only 29 revealed a high intensity peak in the elution step, thus 
being suitable for being considered as I.S, see Figure 10. In the left side of the plot are the 
compounds that were lost in loading sample fraction, while in the right side, starting in 
compound #56, are those that were retained in the loading sample and that were detected in 
the eluted fraction. These fulfill the profile for being selected as I.S. 
Another requirement that the I.S. must fulfill is the adequate retention time, and since 
this parameter varied significantly along the 29 compounds selected, the subsequent step 
(Metabolite extraction) was conducted using mixtures of all of them.  
 
Figure 10 – Fractions obtained  in I.S. tests resorting to C18 tips.  
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4.1.2. Metabolite Extraction 
Membrane enrichment protocol allows separating proteins from metabolites, since the 
soluble part of the sample is separated from the membrane one, which is the focus of this 
project. During this protocol spikes of I.S (using the previously selected 29 compounds) in the 
matrix were made. Four different steps were considered to evaluate the recovery of each 
compound, before ultracentrifugation, before protein precipitation, before C18 tips and 
before HPLC-MS/MS analysis. 
Figure 11 shows the results obtained in the different steps of this protocol. It can be 
seen that compounds #04, #19, #26, #35, #50, #52 and #59 presenting the higher intensities in 
all steps of the protocol are the most interesting ones to be used as I.S. These compounds 
represent also those with the smaller losses between the steps. It should be noted that 
additional tests would be necessary to complete this preliminary search for the ideal I.S. 
However, in order to comply with the main objective of the project on time, the work had to 
proceed with an I.S., Sulfamethazine-D4, commonly used in the laboratory for this type of 
application.  
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Figure 11 – Intensity detected by HPLC-MS, in each step of the membrane enrichment protocol. The blue bar comprises the step before ultracentrifugation; the red bar comprises the step 
before protein precipitation; the green bar, the step before C18 tips and the purple bar represents the step before the HPLC-MS analysis.  
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4.2. Metabolites in pre-frontal cortex samples 
In order to investigate possible alterations in metabolites promoted by the effect of the 
three different drugs studied, each sample was compared with control samples obtained from 
mice free of any drug.  
 
Control vs Citalopram 
As referred before, after the normalization of the peak areas with that of the I.S, 
Sulfamethazine-D4 (283.11 m/z and 17.44 retention time) a PCA was performed. Figure 12 
displays a composed view of the samples in the new orthonormal principal component 
system. This representation, in two dimensions, shows a significant overlap between 
citalopram(Cl) and control (CT) samples. It is seen that the first two principal components are 
able to recover ca. 44%. and 21%, respectively, of the data variability. 
 
 
Figure 12 - Representation of samples on the main two principal components. Panel (a) corresponds to the scatter plot of 
correlation scores with ca. 65% of information recovery. The global set contains 4 samples for each type, control (blue) and 
citalopram (yellow). Panel (b) depicts the respective loadings.  
 
In order to improve  the distinction between both groups a new PCA was performed  on 
217 peaks selected with a t-test (p-value < 0.05). The results presented in Figure 13 show that 
the first component contains, in fact, the most relevant information for discrimination. The 
two first principal components are able to recover ca. 77% of the data variability. The 
inspection of panel (a) clearly shows that a graphical representation based on these two 
a) b) 
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components is clearly meaningful and the discrimination between citalopram samples and 
control ones lies essentially on PC1 which retain ca. 66% of the information. The relevance of 
each peak, in the first two components (PC1 and PC2) is presented in panel (b) of Figure 13. 
The criterion for selecting a significant loading is based on the comparison to the average 
value in each component, i.e., the loading is simply considered significant if above the average 
value defined by 1 √𝑚⁄ , and not significant otherwise, where m stands for the number of 
peaks.  A full description of this approach can be found in reference [93]. 
 
 
Figure 13- PCA results obtained for Control and Citalopram groups.  Panel (a) shows the relative positioning of each sample in 
PC1 vs. PC2 plane corresponding to ca. 77% of information recovery. Panel (b) displays the respective loadings. Complete list 
of significant loadings in Table S5 in supplementary material. 
 
Inspecting the scores and the loading values of each peak it is concluded that the first 
component retains mainly information over peaks (55), (56), (6752), (12817), (2865), (22795), 
(4970), (8588), (24237), (22803), (24235) and (23968) (see the complete list of significant 
loadings in Table S5 in supplementary material). It is seen that samples spread essentially 
along PC1, but PC2 also contributes for the intra-group discrimination. Most of the samples 
are placed in the PC1 vs PC2 plane in such a manner that the closest samples (for example Cl1, 
Cl3 and Cl4) are those with similar peak profile. To further improve the system resolution a 
Mann-Whitney test was performed and 75 peaks with p-value <0.05 were obtained (see Table 
S2 in supplementary material, with the ratio values). Figure 14 shows that using a significantly 
lower number of variables the discrimination between drug sample and control ones is 
preserved. It is possible to identify the peaks that characterize each group. In this case 
a) b) 
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discrimination is based mainly on peaks (22795), (22803), (18535), (24237), (4970), (24235), 
(8714), (2865), (3512) and (4686).  
 
 
Figure 14 - Plot of the two principal components in a PCA between Control and Citalopram groups. The plot it was made by all 
interesting ions found after peak integration and a Mann Whitney test, without CV calculation. Complete list of loadings in 
Table S6 in supplementary material. 
 
At a later stage from the 75 peaks previously selected, only those with a coefficient of 
variation lower than 30% and simultaneously present in the control and drug samples were 
considered (see Table 3). The former criterion intends to keep in each group the peaks that 
preserve the group homogeneity while the latter intends to remove potential errors arisen 
from the alignment procedures. Table 3 contains the values of the mean and standard 
deviation for each group together with the respective coefficient of variation. In the last 
column, and only to assist data interpretation, is qualitatively indicated which group has the 
greater variability, green arrow when citalopram samples shows higher variability and red 
when otherwise.  
  
a) b) 
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Table 3 – Values of mean, standard deviation and CV for citalopram and control samples. Last column represents for each 
peak which the group that presents the higher variability. Green arrow when citalopram samples show higher variability and 
red when otherwise. 
Peak name ((m/z)/RT) μ (CT) σ (CT) μ (CI) σ (CI) CV (CT) (%) CV (CI) (%)  
321.1/17.4  0.024 0.006 0.043 0.012 25.9 28.1 ↑ 
1304.2/38.9  0.058 0.017 0.023 0.001 28.7 4.2 ↓ 
538.8/39.0  0.161 0.026 0.063 0.006 15.9 9.7 ↓ 
800.8/35.8  0.040 0.006 0.019 0.002 14.9 11.5 ↓ 
793.4/38.6  0.288 0.068 0.113 0.017 23.6 15.1 ↓ 
1558.9/38.8  0.032 0.009 0.014 0.002 27.8 12.1 ↓ 
384.0/18.9 0.053 0.014 0.025 0.005 26.6 18.7 ↓ 
792.9/38.8 0.060 0.010 0.031 0.005 16.2 15.7 ↓ 
252.1/18.7  0.023 0.005 0.012 0.002 22.7 17.7 ↓ 
1891.1/38.8 0.009 0.002 0.004 0.001 22.8 17.1 ↓ 
508.0/38.0 0.053 0.015 0.021 0.003 28.9 12.1 ↓ 
288.3/35.4  0.056 0.017 0.027 0.008 29.8 29.3 ↓ 
1048.1/38.9  0.034 0.009 0.019 0.003 25.1 13.6 ↓ 
212.2/27.5  0.060 0.004 0.046 0.011 6.0 22.8 ↑ 
195.1/29.5  0.012 0.001 0.009 0.002 9.4 21.9 ↑ 
622.7/18.9  0.015 0.002 0.007 0.002 12.6 29.7 ↑ 
527.2/34.5  0.011 0.003 0.007 0.001 23.3 14.5 ↓ 
415.1/35.9  0.084 0.009 0.055 0.007 10.4 12.9 ↑ 
792.4/38.9  0.027 0.003 0.010 0.001 11.5 13.6 ↑ 
 
A new PCA was performed using the new set containing the 19 selected peaks. The 
results are displayed in Figure 15. It can be observed that a similar pattern is obtained in this 
simplified system. The first principal component is responsible for the separation between 
citalopram and control samples. Inspecting the scores and the loading values of each peak it 
can be seen that peaks (22795), (8714), (24317) and (7262) are those that allow to preserve 
the discrimination between control and citalopram samples. It should also be noted that the 
administration of citalopram seems to reduce some of the internal variability which is 
reflected in the projection of citalopram samples on the first principal component. 
In order to support the previous results a parallel analysis was performed using the 
fragmentation mass spectra of each of the ions with significant loadings for PC1 (see Table S7 
in supplementary material). From these, and due to software requirements, it was only 
possible to obtain the fragmentation mass spectra for those with m/z <1000 ( m/z = 538.8, 
793.4, 508.0, see Figures S1 to S3 in supplementary material). Finally, the precursors and their 
fragments were compared with the data available in MyCompoundID and Metlin metabolites 
databases. No matching could be found for these metabolites.  
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Figure 15- Representation of citalopram and control samples in the new coordinate system (with ca. 95% of information 
recovery) considering the 19 points with a CV<30%. Complete list of loadings in Table 13 in supplementary material. 
 
The same type of approach has been conducted for haloperidol and clozapine. The same 
analysis steps previously described were applied in order to progressively reduce the dataset. 
Briefly, these include the following steps (i) PCA on the global set of normalized peak areas; (ii) 
PCA on peaks selected by a t-test ( p-value < 0.05); (iii) Mann-Whitney test followed by PCA of 
the variables with p-value < 0.05; (iv)  PCA on the variables with a coefficient of variation <30%  
and simultaneously present in the control and drug samples. 
Finally, the fragmentation mass spectra of the selected ions was studied and the 
selected precursors and their fragments were compared with the data available in 
metabolites databases. Table 4 summarizes the size of the dataset studied by PCA in each step 
for haloperidol and clozapine.  
Table 4 - Overview of dataset size in each of the four main steps for which PCA was performed. 
 Size of the dataset in each subsequent analyses step 
 Global set (m/z) t-test Mann-Whitney test CV< 30% 
Citalopram 21 510 217 75 19 
Haloperidol 30 803 147 17 4 
Clozapine 20 481 279 57 19 
 
a) b) 
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Due to the similarity of the data analysis, and in order to avoid an exhaustive and 
repetitive description only a brief summary of the main results obtained for haloperidol and 
clozapine will be made hereafter. 
In the case of haloperidol, and as observed for citalopram, no distinction could be found 
between drug and control samples in the first PCA (see Figure 16). PCA over the set of 147 
selected peaks (step ii) revealed a clear separation of the two groups of samples along the 
first principal component provided mainly by peaks (938), (12197), (483), (944), (3843), 
(11780), (32401), (5077), (3593) and (7845), (see Figure 17). This distinction along PC1 
remains as the dataset size decreases,  see Figure 18 (and Table S3 in supplementary 
material). It is interesting to note that the information retained in the remaining 4 peaks 
(Table 5 and Figure 19) is sufficient to discriminate haloperidol and control samples. This 
discrimination is provided by peaks (11154) and (33604). In this case, and as occurred for 
citalopram, no correspondence could be found between the precursors selected or the 
corresponding fragments (Figure S4 in supplementary material) and the data available in the 
surveyed databases. It should be noted that the reduced size sets must be regarded with 
some caution, since they may be partially produced by accidental discriminative variables. 
 
 
Figure 16 - Representation of Haloperidol and control samples in the new coordinate system. Blue refers to control samples 
and green to haloperidol.  
a) b) 
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Figure 17 - Representation of haloperidol and control samples in the new coordinate system (with ca. 80% of information 
recovery). Blue refers to control samples and green to haloperidol ones. Complete list of significant loadings in Table S8 of 
supplementary material. 
 
 
 
Figure 18 - Representation of haloperidol and control samples in the new coordinate system (with ca. 71% of information 
recovery). Blue refers to control samples and green to haloperidol ones. PCA was performed on ions selected after peak area 
integration and Mann Whitney test. Complete list of loadings in Table S9 of supplementary material. 
 
Table 5 - Values of mean, standard deviation and CV for haloperidol and control samples. Last column represents for each 
peak which is the group that presents the higher variability. Green arrow when haloperidol samples shows higher variability 
and red when otherwise. 
Peak name ((m/z)/RT) μ (CT) σ (CT) μ (HA) σ (HA) CV (CT) (%) CV (HA) (%)  
538.8/39.0 0.031 0.004 0.022 0.003 11.2 13.0 ↑ 
1304.2/38.9 0.012 0.002 0.009 0.002 19.7 17.9 ↓ 
843.3/32.2 0.002 0.000 0.002 0.001 14.4 27.0 ↑ 
192.0/18.7 0.006 0.001 0.005 0.001 22.7 26.7 ↑ 
a) b) 
a) b) 
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Figure 19- Representation of haloperidol and control samples in the PC1 vs. PC2 plane (panel a) and the contribution of each 
peak of Table 5 for the new coordinate system is represented in panel b. Complete list of loadings in Table S10 of 
supplementary material. 
 
For Clozapine, the PCA on the global dataset shows that the discrimination between 
clozapine and control samples is made essentially along the second component (see Figure 
20). The latter contains ca. 17% of the data variability. For example, peaks (7718), (713), 
(7768), (6592) and (23523) are the ones that contributes more for the discrimination between 
groups (along PC2). Note that the separation between samples of the same group occurs 
along PC1 (with 45.3% of information recovery), being more notorious in the control group.  
The further simplification of the dataset (see Figures 21 to 23 and Table 6) clearly 
improves the discrimination between clozapine and control samples. The peaks responsible 
for the discrimination are (22143), (22151), (23574), (23572), (8385) and (9160). As previously 
described the study of the fragmentation of the precursors was carried out (Figures S5 to S7 in 
supplementary material) and the matching between one of the precursors and the data 
available in the databases was achieved. The molecule with m/z 554.3, matches with an entry 
of the MyCompoundID database (see the corresponding snapshot in Figure 24). According to 
this database, this molecule is a lysophospholipid (LPL), it is an endogenous molecule with 
biofunction in cell signaling, membrane integrity/stability, among others. The information on 
the database also indicates that this molecule is present in all tissues in the extracellular 
environment or in the membrane.  
a) b) 
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Figure 20 - Representation of Clozapine and control samples in the new coordinate system (with ca. 63% of information 
recovery). Blue refers to control samples and red to clozapine ones. PCA was performed on the global m/z dataset.  
 
 
 
Figure 21 – Representation of Clozapine and control samples in the new coordinate system (with ca. 83% of information 
recovery). Blue refers to control samples and red to clozapine ones. PCA was performed on the selected 279 peaks. Complete 
list of significant loadings in Table S11 of supplementary material. 
a) b) 
a) b) 
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Figure 22 - Representation of Clozapine and control samples in the PC1 vs PC2 plane (with ca. 80% of information recovery). 
Blue refers to control samples and red to clozapine ones. PCA was performed on the ions selected after peak integration and 
Mann Whitney test. Complete list of loadings in Table S12 of supplementary material. 
 
Table 6 - Results obtained by calculating the mean and standard deviation of ratios for each sample and after that calculate 
the CV.  
Peak name ((m/z)/RT) μ (CT) μ (CL) σ (CT) σ (CL) CV % (CT) CV % (CL)  
513.3/34.5 0.012 0.007 0.002 0.001 17.5 13.7 ↓ 
487.1/36.1 0.008 0.004 0.002 0.001 24.7 16.4 ↓ 
1303.7/38.8 0.012 0.005 0.003 0.001 23.2 14.8 ↓ 
1814.0/39.0 0.002 0.001 0.000 0.000 12.3 16.1 ↑ 
1304.2/38.9 0.012 0.005 0.002 0.001 19.7 13.8 ↓ 
538.8/39.0 0.032 0.016 0.004 0.002 11.3 13.5 ↑ 
1049.1/38.9 0.034 0.015 0.007 0.002 20.8 13.4 ↓ 
1558.9/38.7 0.005 0.003 0.001 0.000 20.8 9.5 ↓ 
554.3/45.2 0.024 0.039 0.005 0.009 22.6 22.4 ↓ 
793.4/38.8 0.057 0.029 0.009 0.004 15.5 14.7 ↓ 
792.4/38.9 0.005 0.002 0.001 0.001 11.0 22.5 ↑ 
473.1/33.3 0.004 0.002 0.001 0.001 22.5 29.3 ↑ 
793.9/38.8 0.047 0.023 0.008 0.003 17.3 14.5 ↓ 
1559.9/38.8 0.012 0.008 0.003 0.001 24.3 8.1 ↓ 
1048.6/38.9 0.032 0.015 0.007 0.003 20.9 17.1 ↓ 
1559.4/39.0 0.007 0.004 0.002 0.000 25.4 11.3 ↓ 
627.3/22.9 0.004 0.003 0.000 0.001 8.9 21.1 ↑ 
493.2/39.1 0.004 0.003 0.001 0.000 30.0 14.5 ↓ 
486.1/36.1 0.005 0.004 0.000 0.000 8.4 12.2 ↑ 
a) b) 
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Figure 23- Representation of Clozapine and control samples in the PC1 vs PC2 plane (with ca. 95% of information recovery). 
Blue refers to control samples and red to clozapine ones. PCA was performed on the ions selected by CV<30%. Complete list 
of loadings in Table S13 of supplementary material. 
 
 
 
 
 
Figure 24 – Correspondence between the selected ion and the identification in the MyCompoundID database. 
 
a) b) 
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5.  Conclusions and future 
perspectives 
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This project was intended to identify molecules that might be potential biomarkers of 
schizophrenia, in samples of prefrontal cortex of mice. Specifically, the main focus was the 
study and identification of metabolites that might be altered by the effect of three different 
drugs, haloperidol, citalopram and clozapine. The data were collected resorting to HPLC-MS 
analysis.  
Relatively simple and well known chemometrics techniques provided the tools for an in 
depth scrutiny of the distribution of m/z peaks. PCA allowed the direct visualization of data 
structure and also provided the relative positioning of the samples. The most discriminating 
peaks were identified. A fundamental question concerns the normalization of the data, which 
in this case was achieved by the use an appropriate internal standard. Another important 
issue is the reduced size datasets, which must be analyzed and interpreted carefully mostly 
because they may contain artificially discriminative variables.  
In summary, the use of standard multivariate analysis techniques facilitated 
interpretation, allowed graphical visualization of the potential biomarkers profile and can be 
used in an almost automated sequence in this kind of studies. 
It must however be stressed that, although it was possible to identify a potential 
biomarker, research is underway to identify further molecules. Future work will also include 
the application of other techniques such as hierarchical cluster analysis and linear 
discriminant analysis and a detailed inspection of the behavior of the possible biomarkers, 
including a check of the respective variation, for example the effect of dosage on biomarker 
response. Finally, it will be also interesting to include in the analysis a positive control.    
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A) Internal standard tests  
Table S 1 – Compounds names and respective concentration used. 
 Name Conc (mM) 
#01 Amoxicillin trihydrate VETRANAL®. analytical standard 1.08 
#03 Brombuterol hydrochloride VETRANAL®. analytical standard 1.08 
#04 Cefquinome Sulfate 0.73 
#05 Ceftiofur VETRANAL®. analytical standard 0.37 
#06 Chloramphenicol ≥98% (TLC) 0.63 
#07 Chlortetracycline hydrochloride VETRANAL®. analytical standard 0.84 
#08 Cimaterol VETRANAL®. analytical standard 1.82 
#09 cimbuterol 1.71 
#10 clenbuterol hydrochloride 1.44 
#11 clencyclohexerol 1.25 
#12 Clenproperol VETRANAL®. analytical standard 1.52 
#19 Doxycycline hyclate VETRANAL®. analytical standard 0.88 
#21 florfenicol 1.14 
#22 Gamithromycin (Zactran) 0.51 
#26 Isoxsuprine hydrochloride analytical standard. for drug analysis 1.41 
#27 lincomycin hydrochloride monohydrate 1.13 
#28 Mabuterol hydrochloride VETRANAL®. analytical standard  1.29 
#29 Mapenterol hydrochloride VETRANAL®. analytical standard 0.61 
#30 Medroxyprogesterone 17-acetate VETRANAL®. analytical standard 1.04 
#31 Megestrol acetate VETRANAL®. analytical standard 1.2 
#32 Melengestrol acetate VETRANAL®. analytical standard 1.05 
#34 Monensin sodium salt hydrate 0.66 
#35 Narasin from Streptomyces auriofaciens 0.26 
#36 Metaproterenol hemisulfate salt (orciprenalin) 1.83 
#37 Oxytetracycline hydrochloride VETRANAL®. analytical standard 0.85 
#38 Prednisolone 21-acetate VETRANAL®. analytical standard 0.98 
#39 Ractopamine hydrochloride VETRANAL®. analytical standard 1.37 
#40 Ritodrine hydrochloride 1.39 
#41 Robenidine hydrochloride VETRANAL®. analytical standard 1.2 
#42 Salbutamol 1.57 
#43 Salmeterol xinafoate 0.94 
#45 Sulfachloropyridazine VETRANAL®. analytical standard 1.42 
#46 Sulfadiazine VETRANAL®. analytical standard (Fluka) 1.69 
#47 Sulfadimethoxine VETRANAL®. analytical standard 1.31 
#48 Sulfadoxin VETRANAL®. analytical standard 1.40 
#49 Sulfamethazine VETRANAL®. analytical standard 1.39 
#50 Sulfamethoxypyridazine VETRANAL®. analytical standard 1.44 
#51 Terbutalin sulfate 1.73 
#52 Tetracycline hydrochloride 0.96 
#53 Tiamulin VETRANAL®. analytical standard 8.09 
#54 Tilmicosin - VETRANAL®. analytical standard (Fluka) 0.46 
#55 Trenbolone acetate 1.30 
#56 Triamcinolone acetonide analytical standard 0.91 
#57 Trimethoprim VETRANAL®. analytical standard 1.38 
#58 Tulathromycin (Draxxin) 0.50 
#59 Tulobuterol hydrochloride VETRANAL®. analytical standard 1.72 
#60 Tylosin tartrate VETRANAL®. analytical standard 0.41 
#61 Valnemulin VETRANAL®. analytical standard 0.69 
#62 α-Zearalanol ~97% (HPLC) 0.12 
#63 Zilpaterol HCl 0.76 
#96 Clenpenterol hydrochloride VETRANAL®. analytical standard 1.37 
#98 Penicilline V potassium salt 1.28 
#99 Sulfamethazine-D4 0.14 
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B) Ratios and fragmentation mass spectra 
 
i. Control vs Citalopram 
Table S 2 - Ratios obtained for Control and Citalopram samples, considering the I.S and the reduced set of 75 variables. 
Peak name ((m/z)/RT) CT1 CT2 CT3 CT4 CI1 CI2 CI3 CI4 
175.0/19.1 0.007 0.012 0.006 0.007 0.006 0.006 0.004 0.003 
607.7/35.9 0.042 0.021 0.034 0.032 0.018 0.017 0.005 0.013 
321.1/17.4 0.026 0.015 0.027 0.029 0.032 0.058 0.050 0.035 
282.3/39.4 0.000 0.000 0.011 0.000 0.020 0.013 0.021 0.012 
1303.7/38.8 0.050 0.054 0.048 0.091 0.020 0.023 0.023 0.025 
323.1/19.0 0.009 0.020 0.010 0.000 0.035 0.033 0.056 0.040 
1304.2/38.9 0.049 0.051 0.051 0.083 0.022 0.024 0.024 0.023 
538.8/39.0 0.151 0.134 0.166 0.195 0.065 0.057 0.071 0.061 
385.1/18.9 0.034 0.056 0.036 0.042 0.016 0.030 0.029 0.017 
245.1/23.5 0.012 0.026 0.020 0.058 0.067 0.134 0.098 0.127 
800.8/35.8 0.036 0.044 0.034 0.046 0.020 0.021 0.016 0.019 
1049.1/38.6 0.143 0.154 0.129 0.246 0.057 0.059 0.069 0.069 
793.4/38.6 0.250 0.269 0.245 0.389 0.102 0.098 0.136 0.118 
1059.6/38.9 0.003 0.003 0.005 0.009 0.012 0.013 0.014 0.016 
1558.9/38.8 0.029 0.027 0.026 0.045 0.014 0.012 0.016 0.016 
1048.6/38.9 0.136 0.140 0.128 0.232 0.061 0.058 0.072 0.075 
457.1/32.3 0.002 0.006 0.010 0.009 0.044 0.024 0.073 0.031 
325.2/25.1 0.211 0.126 0.149 0.100 0.006 0.003 0.015 0.003 
354.1/36.1 0.017 0.025 0.021 0.033 0.013 0.010 0.006 0.007 
1559.4/39.0 0.032 0.028 0.032 0.055 0.013 0.015 0.017 0.016 
793.9/38.6 0.193 0.212 0.201 0.324 0.083 0.081 0.107 0.100 
414.2/37.6 0.002 0.002 0.013 0.002 0.018 0.028 0.022 0.014 
277.1/30.8 0.003 0.005 0.004 0.012 0.014 0.018 0.037 0.017 
487.1/35.8 0.053 0.040 0.035 0.069 0.012 0.027 0.007 0.012 
384.0/18.9 0.041 0.062 0.042 0.069 0.020 0.024 0.031 0.027 
792.9/38.8 0.055 0.050 0.063 0.072 0.025 0.028 0.035 0.035 
219.0/18.9 0.021 0.037 0.017 0.043 0.015 0.016 0.004 0.004 
492.3/35.3 0.044 0.066 0.025 0.065 0.016 0.019 0.010 0.032 
537.8/38.6 0.026 0.024 0.036 0.041 0.010 0.018 0.003 0.016 
457.1/33.2 0.007 0.004 0.005 0.004 0.028 0.009 0.041 0.022 
297.1/17.5 0.030 0.045 0.029 0.049 0.012 0.018 0.026 0.027 
252.1/18.7 0.017 0.023 0.023 0.030 0.009 0.012 0.013 0.014 
624.2/18.9 0.029 0.047 0.052 0.081 0.025 0.023 0.030 0.024 
1891.1/38.8 0.010 0.006 0.008 0.011 0.005 0.003 0.004 0.004 
660.2/9.5 0.001 0.002 0.004 0.006 0.017 0.017 0.026 0.034 
433.3/31.9 0.012 0.024 0.008 0.013 0.008 0.002 0.011 0.004 
486.1/36.1  0.021 0.024 0.022 0.030 0.014 0.018 0.006 0.009 
1559.9/39.0 0.050 0.050 0.047 0.089 0.025 0.027 0.032 0.034 
425.1/35.9  0.004 0.093 0.011 0.101 0.303 0.181 0.210 0.178 
355.0/33.2 0.031 0.029 0.024 0.028 0.018 0.008 0.015 0.011 
508.0/38.0 0.048 0.037 0.053 0.073 0.018 0.024 0.022 0.020 
315.0/23.9  0.005 0.004 0.004 0.008 0.001 0.002 0.002 0.004 
747.5/39.1  0.000 0.000 0.001 0.000 0.013 0.003 0.008 0.007 
667.3/29.2  0.007 0.018 0.002 0.011 0.001 0.000 0.002 0.003 
288.3/35.4  0.042 0.055 0.047 0.079 0.039 0.023 0.027 0.022 
328.1/9.7  0.000 0.002 0.013 0.009 0.035 0.015 0.038 0.055 
1048.1/38.9  0.029 0.029 0.032 0.047 0.016 0.018 0.022 0.018 
326.1/33.1  0.002 0.007 0.003 0.001 0.016 0.008 0.012 0.012 
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Table S 2 – (cont.) 
466.9/37.7  0.021 0.021 0.026 0.043 0.010 0.015 0.017 0.010 
629.2/18.7  0.015 0.021 0.017 0.025 0.011 0.010 0.007 0.001 
212.2/27.5  0.054 0.062 0.060 0.062 0.053 0.031 0.052 0.049 
241.0/13.9  0.011 0.023 0.017 0.034 0.010 0.000 0.010 0.001 
378.2/18.3  0.013 0.020 0.003 0.014 0.003 0.001 0.004 0.002 
523.3/25.5  0.077 0.106 0.059 0.138 0.045 0.018 0.076 0.050 
268.2/21.0  0.014 0.024 0.018 0.017 0.012 0.004 0.013 0.015 
713.4/32.6  0.003 0.005 0.002 0.005 0.001 0.001 0.002 0.002 
195.1/29.5  0.012 0.012 0.011 0.013 0.008 0.006 0.010 0.010 
622.7/18.9  0.012 0.015 0.016 0.016 0.007 0.006 0.010 0.005 
268.1/26.1 0.025 0.032 0.022 0.065 0.010 0.011 0.016 0.016 
598.3/26.7  0.014 0.032 0.018 0.031 0.008 0.006 0.007 0.004 
312.1/18.7  0.035 0.059 0.035 0.065 0.018 0.014 0.002 0.031 
326.1/9.5  0.000 0.002 0.000 0.009 0.022 0.013 0.035 0.042 
514.3/25.5 0.030 0.060 0.016 0.042 0.010 0.007 0.024 0.012 
584.3/39.3  0.005 0.004 0.005 0.003 0.001 0.000 0.001 0.004 
519.3/32.5  0.015 0.026 0.010 0.025 0.009 0.001 0.014 0.006 
527.2/34.5  0.008 0.014 0.009 0.012 0.008 0.008 0.006 0.008 
415.1/35.9  0.076 0.091 0.078 0.092 0.057 0.062 0.045 0.056 
295.2/39.0  0.052 0.108 0.027 0.046 0.019 0.015 0.015 0.027 
263.0/13.9  0.018 0.021 0.019 0.033 0.006 0.004 0.010 0.006 
1074.5/39.2  0.032 0.053 0.047 0.072 0.023 0.024 0.027 0.028 
792.4/38.9  0.024 0.025 0.027 0.031 0.008 0.011 0.012 0.011 
354.3/45.2  0.083 0.088 0.032 0.151 0.021 0.032 0.007 0.027 
555.3/38.6 0.014 0.007 0.009 0.012 0.003 0.006 0.005 0.001 
409.3/21.1 0.055 0.117 0.055 0.096 0.045 0.013 0.011 0.010 
684.4/44.0 0.293 0.271 0.268 0.371 0.201 0.128 0.012 0.218 
 
 
 
Figure S 1 – Fragmentation mass spectrum of the precursor with a m/z value of 538.8, in positive mode. 
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Figure S 2 -- Fragmentation mass spectrum of the precursor with a m/z value of 793.4, in positive mode. 
 
 
 
Figure S 3 -- Fragmentation mass spectrum of the precursor with a m/z value of 508.0, in positive mode. 
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ii. Control vs Haloperidol 
 
Table S 3 - Ratios obtained for Control and Haloperidol samples, considering the I.S and the reduced set of 17 variables. 
Peak name ((m/z)/RT) CT1 CT2 CT3 CT4 HA1 HA2 HA3 HA4 
538.8/39.0 0.031 0.027 0.033 0.035 0.019 0.021 0.025 0.024 
294.1/35.9 0.002 0.004 0.002 0.003 0.001 0.004 0.002 0.001 
197.2/30.2 0.005 0.005 0.005 0.004 0.008 0.006 0.012 0.012 
536.3/45.4 0.004 0.001 0.002 0.001 0.004 0.004 0.004 0.005 
1304.2/38.9 0.010 0.010 0.012 0.015 0.009 0.008 0.011 0.007 
508.3/33.3 0.011 0.007 0.011 0.008 0.011 0.002 0.014 0.003 
258.1/34.9 0.003 0.003 0.004 0.001 0.006 0.006 0.005 0.007 
456.3/14.8 0.003 0.002 0.003 0.002 0.003 0.004 0.007 0.005 
260.2/38.7 0.008 0.012 0.012 0.004 0.020 0.015 0.018 0.017 
485.4/13.4 0.014 0.003 0.010 0.004 0.017 0.004 0.009 0.007 
843.3/32.2 0.002 0.002 0.002 0.001 0.002 0.001 0.002 0.002 
192.0/18.7 0.004 0.006 0.006 0.007 0.004 0.004 0.006 0.005 
277.1/13.4 0.001 0.001 0.001 0.002 0.007 0.001 0.004 0.005 
510.3/30.7 0.003 0.003 0.003 0.006 0.014 0.003 0.005 0.005 
218.1/11.5 0.002 0.002 0.002 0.003 0.000 0.003 0.004 0.003 
594.2/18.9 0.002 0.001 0.003 0.002 0.001 0.002 0.001 0.001 
208.2/30.2 0.006 0.007 0.010 0.007 0.013 0.011 0.029 0.029 
 
 
 
Figure S 4 - Fragmentation mass spectrum for the precursor with a m/z value of 538.8, in positive mode. 
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iii. Control vs Clozapine 
Table S 4 - Ratios obtained for Control and Clozapine samples, considering the I.S and the reduced set of 57 variables.  
Peak name ((m/z)/RT) CT1 CT2 CT3 CT4 CL1 CL2 CL3 CL4 
354.1/36.1 0.004 0.005 0.005 0.006 0.002 0.002 0.001 0.001 
294.1/35.9 0.002 0.004 0.002 0.003 0.001 0.001 0.001 0.001 
660.2/9.5 0.002 0.000 0.002 0.001 0.006 0.004 0.004 0.003 
607.2/35.8 0.011 0.008 0.008 0.008 0.006 0.006 0.002 0.003 
178.2/19.2 0.007 0.004 0.008 0.006 0.004 0.001 0.002 0.002 
800.8/35.8 0.006 0.006 0.006 0.006 0.003 0.003 0.001 0.002 
457.1/33.2 0.001 0.001 0.001 0.001 0.005 0.004 0.003 0.003 
513.3/34.5 0.013 0.014 0.009 0.012 0.008 0.006 0.008 0.007 
487.1/36.1 0.011 0.006 0.008 0.009 0.005 0.004 0.004 0.003 
613.3/22.0 0.002 0.002 0.003 0.002 0.002 0.001 0.002 0.001 
800.3/35.8 0.009 0.010 0.009 0.008 0.005 0.004 0.002 0.003 
292.2/15.6 0.004 0.002 0.002 0.003 0.001 0.000 0.000 0.000 
607.7/35.9 0.007 0.004 0.005 0.004 0.003 0.004 0.003 0.004 
323.1/19.0 0.001 0.003 0.001 0.002 0.004 0.005 0.006 0.004 
301.7/15.6 0.009 0.006 0.006 0.007 0.006 0.000 0.004 0.000 
588.4/44.1 0.004 0.001 0.004 0.004 0.006 0.009 0.007 0.008 
1303.7/38.8 0.010 0.011 0.011 0.016 0.005 0.004 0.005 0.006 
1814.0/39.0 0.002 0.002 0.002 0.003 0.001 0.001 0.001 0.001 
1304.2/38.9 0.010 0.010 0.012 0.015 0.005 0.005 0.006 0.006 
538.8/39.0 0.031 0.027 0.033 0.035 0.014 0.014 0.018 0.017 
790.4/23.4 0.002 0.005 0.002 0.003 0.002 0.001 0.001 0.002 
1049.1/38.9 0.030 0.031 0.030 0.044 0.014 0.013 0.018 0.016 
1558.9/38.7 0.005 0.005 0.005 0.007 0.003 0.002 0.003 0.003 
554.3/45.2 0.026 0.017 0.022 0.029 0.048 0.034 0.045 0.030 
224.1/16.3 0.036 0.042 0.037 0.036 0.009 0.007 0.034 0.030 
793.4/38.8 0.052 0.054 0.051 0.070 0.025 0.026 0.030 0.034 
600.4/15.6 0.012 0.000 0.008 0.000 0.000 0.000 0.000 0.000 
792.4/38.9 0.005 0.005 0.004 0.006 0.002 0.002 0.002 0.003 
473.1/33.3 0.004 0.005 0.003 0.004 0.003 0.002 0.002 0.002 
793.9/38.8 0.040 0.042 0.046 0.058 0.021 0.019 0.023 0.027 
1559.9/38.8 0.010 0.010 0.011 0.016 0.008 0.008 0.007 0.007 
1891.1/38.9 0.001 0.001 0.001 0.001 0.001 0.001 0.000 0.001 
321.1/14.9 0.002 0.006 0.002 0.005 0.007 0.013 0.014 0.007 
464.8/26.7 0.003 0.006 0.001 0.002 0.001 0.001 0.002 0.001 
294.2/14.4 0.005 0.002 0.004 0.002 0.001 0.001 0.001 0.001 
1048.6/38.9 0.028 0.028 0.029 0.042 0.013 0.013 0.017 0.018 
808.8/36.1 0.002 0.002 0.002 0.001 0.001 0.000 0.000 0.001 
1559.4/39.0 0.007 0.006 0.007 0.010 0.003 0.003 0.003 0.004 
627.3/22.9 0.005 0.004 0.004 0.004 0.003 0.002 0.003 0.003 
542.3/38.8 0.001 0.001 0.001 0.002 0.003 0.003 0.004 0.001 
453.2/18.3 0.006 0.014 0.003 0.011 0.019 0.046 0.032 0.011 
493.2/39.1 0.004 0.006 0.004 0.003 0.002 0.003 0.003 0.003 
541.3/19.9 0.005 0.010 0.005 0.010 0.013 0.025 0.025 0.010 
583.3/29.7 0.004 0.007 0.002 0.004 0.001 0.002 0.003 0.001 
409.2/17.3 0.004 0.008 0.001 0.006 0.009 0.021 0.014 0.006 
713.4/32.6 0.001 0.001 0.000 0.001 0.000 0.000 0.000 0.000 
282.3/39.7 0.007 0.003 0.004 0.006 0.013 0.010 0.008 0.008 
506.5/30.8 0.002 0.005 0.002 0.003 0.001 0.001 0.002 0.001 
588.3/31.8 0.007 0.007 0.004 0.006 0.001 0.002 0.003 0.003 
365.2/16.2 0.004 0.007 0.003 0.006 0.009 0.023 0.017 0.007 
508.0/38.0 0.010 0.007 0.012 0.013 0.004 0.004 0.006 0.006 
480.3/41.1 0.000 0.023 0.000 0.000 0.047 0.036 0.037 0.070 
486.1/36.1 0.004 0.005 0.005 0.005 0.004 0.004 0.003 0.004 
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Table S 4 – (cont.) 
283.3/41.8 0.000 0.002 0.000 0.004 0.006 0.004 0.004 0.005 
277.1/13.5 0.001 0.001 0.001 0.002 0.002 0.004 0.006 0.004 
577.2/36.7 0.008 0.004 0.009 0.011 0.008 0.003 0.002 0.004 
550.6/31.4 0.001 0.002 0.001 0.001 0.000 0.000 0.001 0.001 
 
 
 
 
Figure S 5 – Fragmentation mass spectrum for the precursor with a m/z value of 538.8, in positive mode. 
 
 
 
Figure S 6 – Fragmentation mass spectrum for the precursor with a m/z value of 554.3, in positive mode. 
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Figure S 7 - Fragmentation mass spectrum for the precursor with a m/z value of 793.4, in positive mode. 
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C) Loading Values 
 
i. Control vs Citalopram 
Table S 5 - Significant loading values (>0.068) of each variable on the first two principal components. The contributions are 
sorted in descending order along PC1. 
. PC1(66.1%) PC2 (10.9 %) 
150.1/11.0 (55) 0.285 -0.431 
150.1/10.5 (56) 0.245 0.431 
494.3/38.0 (6752) 0.205 0.031 
599.4/15.6 (12817) 0.168 0.122 
325.2/25.1 (2865) 0.162 0.114 
793.4/38.6 (22795) 0.160 -0.194 
425.1/35.9 (4970) 0.158 0.095 
536.3/38.4 (8588) 0.147 -0.013 
1049.1/38.6 (24237) 0.139 -0.164 
793.9/38.6 (22803) 0.134 -0.209 
1048.6/38.9 (24235) 0.132 -0.150 
907.6/45.0 (23968) 0.126 0.049 
538.8/39.0 (8714) 0.115 -0.093 
485.4/13.1 (6474) 0.115 -0.046 
245.1/23.5 (893) 0.107 -0.013 
478.3/37.1 (6262) 0.102 0.025 
360.3/41.9 (3662) 0.100 -0.019 
1304.2/38.9 (24317) 0.099 -0.027 
151.1/11.0 (62) 0.099 -0.130 
457.1/32.3 (5747) 0.098 -0.021 
1303.7/38.8 (24316) 0.095 -0.078 
611.2/38.8 (13646) 0.094 0.073 
548.3/34.0 (9168) 0.093 0.011 
652.4/43.9 (16593) 0.091 -0.010 
254.2/17.0 (1071) 0.091 -0.145 
321.1/17.4 (2759) 0.091 0.041 
302.2/10.8 (2301) 0.086 -0.029 
457.1/33.2 (5746) 0.084 -0.012 
323.1/19.0 (2798) 0.083 -0.030 
607.2/35.7 (13345) 0.083 -0.012 
302.2/10.3 (2304) 0.082 -0.003 
151.1/10.4 (63) 0.081 0.142 
318.2/21.8 (2696) 0.080 -0.066 
537.3/38.4 (8637) 0.080 -0.011 
1559.4/39.0 (24354) 0.080 -0.043 
508.3/34.1 (7277) 0.079 -0.148 
254.2/17.5 (1074) 0.078 -0.035 
734.5/44.8 (21016) 0.078 0.000 
542.3/19.9 (8890) 0.077 -0.018 
567.3/28.5 (10362) 0.077 0.002 
326.2/25.1 (2886) 0.077 0.046 
800.8/35.8 (22960) 0.076 0.026 
297.2/44.3 (2188) 0.076 -0.126 
800.3/35.7 (22944) 0.074 0.043 
523.3/25.5 (7977) 0.074 -0.169 
355.0/32.4 (3520) 0.073 -0.072 
1559.9/39.0 (24355) 0.073 -0.070 
607.7/35.9 (13377) 0.072 -0.001 
505.3/19.6 (7158) 0.070 -0.021 
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Table S 5 – (cont.) 
508.0/38.0 (7262) 0.070 0.007 
434.8/28.8 (5223) 0.070 -0.034 
178.2/19.2 (175) 0.069 0.001 
1558.9/38.8 (24353) 0.068 -0.035 
462.3/45.1 (5862) 0.068 0.009 
583.3/39.2 (11586) 0.068 -0.025 
 
 
 
 
Table S 6 - Loading values of each variable on the first two principal components. The contributions are sorted in descending 
order along PC1(Significant loadings >0.115) 
Peak Name PC1 (76.1 %) PC2 (8.8 %) 
793.4/38.6 (22795) 0.287 0.111 
793.9/38.6 (22803) 0.258 0.129 
684.4/44.0 (18535) 0.255 -0.082 
1049.1/38.6 (24237) 0.225 0.142 
425.1/35.9 (4970) 0.213 0.476 
1048.6/38.9 (24235) 0.212 0.141 
538.8/39.0 (8714) 0.204 -0.061 
325.2/25.1 (2865) 0.202 -0.430 
354.3/45.2 (3512) 0.180 0.153 
409.3/21.1 (4686) 0.156 0.054 
523.3/25.5 (7977) 0.144 0.225 
245.1/23.5 (893) 0.144 0.255 
1303.7/38.8 (24316) 0.136 0.088 
1304.2/38.9 (24317) 0.130 0.063 
487.1/35.8 (6519) 0.124 -0.016 
312.1/18.7 (2541) 0.120 0.056 
1559.9/39.0 (24355) 0.120 0.119 
508.0/38.0 (7262) 0.118 0.006 
492.3/35.3 (6687) 0.116 0.066 
288.3/35.4 (1949) 0.115 0.110 
384.0/18.9 (4143) 0.113 0.086 
323.1/19.0 (2798) 0.112 0.089 
415.1/35.9 (4790) 0.112 -0.019 
792.9/38.8 (22788) 0.111 -0.020 
624.2/18.9 (14619) 0.110 0.145 
1074.5/39.2 (24258) 0.109 0.116 
457.1/32.3 (5747) 0.109 0.173 
268.1/26.1 (1431) 0.106 0.163 
295.2/39.0 (2113) 0.105 -0.029 
1559.4/39.0 (24354) 0.101 0.061 
800.8/35.8 (22960) 0.096 -0.008 
219.0/18.9 (517) 0.095 0.071 
328.1/9.7 (2922) 0.094 0.130 
1558.9/38.8 (24353) 0.091 0.054 
514.3/25.5 (7588) 0.091 0.076 
537.8/38.6 (8652) 0.089 -0.035 
297.1/17.5 (2166) 0.087 0.084 
598.3/26.7 (12734) 0.087 0.053 
263.0/13.9 (1283) 0.087 0.052 
1048.1/38.9 (24234) 0.085 0.060 
241.0/13.9 (809) 0.085 0.103 
792.4/38.9 (22774) 0.083 -0.027 
326.1/9.5 (2878) 0.083 0.164 
354.1/36.1 (3504) 0.083 0.041 
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Table S 6 – (cont.) 
466.9/37.7 (5948) 0.081 0.076 
660.2/9.5 (17101) 0.081 0.113 
457.1/33.2 (5746) 0.081 0.106 
414.2/37.6 (4778) 0.079 0.009 
385.1/18.9 (4181) 0.078 -0.010 
607.7/35.9 (13377) 0.077 -0.155 
321.1/17.4 (2759) 0.075 0.055 
355.0/33.2 (3519) 0.075 -0.052 
282.3/39.4 (1762) 0.074 0.039 
252.1/18.7 (1022) 0.073 0.036 
486.1/36.1 (6492) 0.073 -0.014 
629.2/18.7 (14973) 0.071 0.019 
519.3/32.5 (7790) 0.068 0.080 
212.2/27.5 (454) 0.064 0.032 
378.2/18.3 (4033) 0.062 0.020 
277.1/30.8 (1625) 0.061 0.158 
326.1/33.1 (2879) 0.057 0.051 
622.7/18.9 (14499) 0.056 -0.012 
667.3/29.2 (17555) 0.055 0.036 
1059.6/38.9 (24249) 0.051 0.098 
747.5/39.1 (21525) 0.049 0.060 
433.3/31.9 (5205) 0.047 0.029 
555.3/38.6 (9544) 0.047 -0.050 
268.2/21.0 (1447) 0.044 0.013 
1891.1/38.8 (24414) 0.044 -0.020 
195.1/29.5 (277) 0.037 0.010 
527.2/34.5 (8174) 0.036 0.019 
315.0/23.9 (2624) 0.036 0.030 
713.4/32.6 (20076) 0.032 0.018 
175.0/19.1 (157) 0.030 -0.013 
584.3/39.3 (11665) 0.022 -0.053 
 
 
 
Table S 7 - Loading values of each variable on the first two principal components. The contributions are sorted in descending 
order along PC1(Significant loadings >0.229) 
Peak Name PC1 (90.6 %) PC2 (3.8 %) 
793.4/38.6 (22795) 0.564 0.085 
538.8/39.0 (8714) 0.402 0.110 
1304.2/38.9 (24317) 0.256 0.141 
508.0/38.0 (7262) 0.235 0.322 
288.3/35.4 (1949) 0.227 -0.096 
792.9/38.8 (22788) 0.222 0.145 
384.0/18.9 (4143) 0.220 -0.113 
415.1/35.9 (4790) 0.208 -0.212 
800.8/35.8 (22960) 0.181 -0.161 
1558.9/38.8 (24353) 0.180 0.068 
1048.1/38.9 (24234) 0.171 0.182 
792.4/38.9 (22774) 0.162 0.009 
252.1/18.7 (1022) 0.145 0.029 
321.1/17.4 (2759) 0.137 0.712 
212.2/27.5 (454) 0.131 -0.402 
622.7/18.9 (14499) 0.112 -0.031 
1891.1/38.8 (24414) 0.085 0.051 
195.1/29.5 (277) 0.072 -0.063 
527.2/34.5 (8174) 0.067 -0.169 
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ii. Control vs Haloperidol 
 
Table S 8 - Significant loading values (> 0.082) of each variable on the first two principal components. The contributions are 
sorted in descending order along PC1. 
Peak Name PC1 (66.2 %) PC2 (13.5 %) 
243.2/12.1 (938) 0.322 -0.398 
554.3/45.2 (12197) 0.206 0.173 
211.1/29.6 (483) 0.187 -0.231 
243.7/12.1 (944) 0.174 -0.233 
350.2/17.8 (3843) 0.170 0.116 
548.3/28.7 (11780) 0.167 -0.103 
907.6/45.0 (32401) 0.161 0.179 
399.1/14.6 (5077) 0.157 0.094 
339.3/45.1 (3593) 0.150 -0.001 
482.3/45.1 (7845) 0.143 0.413 
220.1/28.8 (588) 0.133 -0.025 
485.4/13.4 (7972) 0.131 -0.154 
793.4/38.8 (29646) 0.126 -0.135 
130.2/13.9 (17) 0.124 -0.020 
1049.1/38.9 (33225) 0.123 0.027 
251.2/38.0 (1087) 0.122 -0.068 
208.2/30.2 (446) 0.120 0.128 
175.1/33.5 (174) 0.119 0.118 
548.3/34.0 (11773) 0.118 -0.095 
514.3/33.1 (9571) 0.117 0.064 
214.2/30.2 (527) 0.117 0.074 
1048.6/38.9 (33223) 0.116 -0.103 
549.3/28.7 (11856) 0.115 0.021 
508.3/33.3 (9174) 0.112 -0.055 
622.4/43.7 (18317) 0.110 -0.014 
212.2/27.3 (506) 0.109 -0.011 
538.8/39.0 (11154) 0.107 -0.062 
151.1/11.0 (65) 0.099 0.052 
550.3/30.5 (11929) 0.098 -0.091 
607.2/36.1 (16949) 0.097 0.094 
281.2/35.1 (1915) 0.096 0.006 
652.4/44.4 (20875) 0.095 -0.022 
343.2/15.7 (3685) 0.094 0.030 
656.4/35.6 (21239) 0.092 0.005 
569.4/45.1 (13536) 0.092 0.101 
1303.7/38.8 (33603) 0.090 -0.011 
260.2/38.7 (1315) 0.088 -0.021 
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Table S 9 - Loading values of each variable on the first two principal components. The contributions are sorted in descending 
order along PC1(Significant loadings >0.243) 
Peak Name PC1 (50.9 %) PC2 (20.4 %) 
208.2/30.2 (446) 0.500 -0.365 
260.2/38.7 (1315) 0.419 0.059 
538.8/39.0 (11154) 0.377 -0.049 
197.2/30.2 (344) 0.319 -0.137 
258.1/34.9 (1275) 0.247 -0.043 
277.1/13.4 (1805) 0.237 0.173 
1304.2/38.9 (33604) 0.214 0.064 
536.3/45.4 (10966) 0.197 0.006 
456.3/14.8 (6845) 0.189 -0.147 
510.3/30.7 (9296) 0.171 0.413 
485.4/13.4 (7972) 0.157 0.592 
294.1/35.9 (2305) 0.125 -0.152 
594.2/18.9 (15766) 0.106 0.015 
192.0/18.7 (265) 0.091 -0.115 
843.3/32.2 (31373) 0.054 0.070 
508.3/33.3 (9174) 0.007 0.376 
218.1/11.5 (561) 0.002 -0.284 
 
Table S 10 - Loading values of each variable on the first two principal components. The contributions are sorted in descending 
order along PC1 (Significant loadings >0.500). 
Peak Name PC1 (83.0 %) PC2 (9.4 %) 
538.8/39.0 (11154)  0.815 -0.559 
1304.2/38.9 (33604) 0.500 0.608 
192.0/18.7 (265) 0.289 0.477 
843.3/32.2 (31373) 0.046 -0.302 
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iii. Control vs Clozapine 
 
Table S 11 - Significant loading values (> 0.060) of each variable on the first two principal components. The contributions are 
sorted in descending order along PC1. 
Peak Name PC1 (71.8 %) PC2 (11.4 %) 
238.1/17.2 (713) 0.427 0.548 
238.1/16.7 (712) 0.321 0.277 
316.2/15.2 (2591) 0.253 0.135 
316.2/14.7 (2596) 0.251 0.173 
496.3/43.6 (6594) 0.190 0.242 
300.2/15.6 (2192) 0.174 0.138 
150.1/11.2 (54) 0.174 0.121 
300.2/16.9 (2193) 0.162 -0.028 
243.2/13.3 (809) 0.150 0.021 
522.3/44.9 (7616) 0.137 -0.005 
150.1/10.5 (53) 0.128 0.066 
494.3/37.9 (6484) 0.115 -0.006 
221.1/18.3 (517) 0.107 0.099 
523.4/44.4 (7663) 0.103 0.055 
300.7/15.6 (2204) 0.102 0.081 
497.3/43.8 (6640) 0.100 0.129 
300.7/16.9 (2205) 0.097 -0.023 
350.2/17.8 (3294) 0.095 0.071 
612.4/17.8 (13396) 0.090 0.050 
285.1/17.1 (1777) 0.089 0.237 
599.4/15.6 (12449) 0.088 0.071 
285.1/17.6 (1778) 0.088 -0.255 
306.7/17.8 (2336) 0.086 0.048 
243.7/13.3 (818) 0.083 0.018 
317.2/13.4 (2618) 0.078 0.063 
178.2/17.7 (172) 0.077 0.002 
536.3/38.3 (8265) 0.075 0.039 
350.2/18.3 (3293) 0.075 0.007 
317.2/13.9 (2617) 0.074 -0.007 
224.1/16.3 (556) 0.070 -0.041 
178.1/12.6 (164) 0.068 0.050 
301.2/15.6 (2214) 0.065 0.045 
599.4/16.9 (12451) 0.065 -0.017 
793.4/38.8 (22143) 0.064 0.124 
1049.1/38.9 (23574) 0.063 0.082 
130.2/14.5 (13) 0.062 0.009 
216.2/15.2 (460) 0.062 0.026 
554.3/45.2 (9160) 0.060 -0.053 
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Table S 12 -  Loading values of each variable on the first two principal components. The contributions are sorted in 
descending order along PC1  (Significant loadings >0.132). 
Peak Name PC1 (70.4 %) PC2 (9.9 %) 
480.3/41.1 (6063) 0.323 -0.382 
793.4/38.8 (22143) 0.300 0.141 
793.9/38.8 (22151) 0.279 0.112 
1049.1/38.9 (23574) 0.241 0.169 
1048.6/38.9 (23572) 0.228 0.141 
453.2/18.3 (5394) 0.228 0.476 
538.8/39.0 (8385) 0.225 0.068 
224.1/16.3 (556) 0.216 -0.034 
554.3/45.2 (9160) 0.185 0.038 
541.3/19.9 (8503) 0.169 0.346 
365.2/16.2 (3596) 0.160 0.322 
409.2/17.3 (4472) 0.150 0.311 
1303.7/38.8 (23650) 0.147 0.073 
1304.2/38.9 (23651) 0.139 0.110 
321.1/14.9 (2694) 0.133 0.231 
508.0/38.0 (6993) 0.133 0.050 
800.3/35.8 (22292) 0.119 -0.019 
513.3/34.5 (7246) 0.110 0.016 
1559.9/38.8 (23689) 0.108 0.130 
1559.4/39.0 (23688) 0.108 0.052 
487.1/36.1 (6256) 0.108 0.023 
178.2/19.2 (170) 0.108 -0.091 
607.2/35.8 (12991) 0.107 -0.001 
588.4/44.1 (11594) 0.106 0.033 
577.2/36.7 (10748) 0.103 -0.067 
301.7/15.6 (2226) 0.102 -0.021 
588.3/31.8 (11592) 0.102 0.022 
282.3/39.7 (1680) 0.101 -0.044 
800.8/35.8 (22309) 0.100 0.029 
354.1/36.1 (3386) 0.099 0.067 
600.4/15.6 (12510) 0.093 -0.126 
660.2/9.5 (16696) 0.093 -0.040 
1558.9/38.7 (23687) 0.092 0.046 
792.4/38.9 (22123) 0.090 0.018 
323.1/19.0 (2725) 0.089 0.111 
457.1/33.2 (5503) 0.086 -0.044 
292.2/15.6 (1966) 0.086 -0.010 
283.3/41.8 (1723) 0.084 -0.019 
294.2/14.4 (2016) 0.072 -0.095 
473.1/33.3 (5865) 0.068 -0.014 
277.1/13.5 (1550) 0.066 0.091 
627.3/22.9 (14456) 0.064 -0.076 
583.3/29.7 (11241) 0.064 0.098 
294.1/35.9 (2008) 0.060 0.057 
607.7/35.9 (13026) 0.060 -0.047 
506.5/30.8 (6933) 0.060 0.052 
486.1/36.1 (6230) 0.059 -0.013 
542.3/38.8 (8560) 0.059 0.112 
1814.0/39.0 (23720) 0.058 0.021 
808.8/36.1 (22472) 0.056 -0.068 
464.8/26.7 (5652) 0.050 0.052 
493.2/39.1 (6445) 0.050 0.024 
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Table S 12 – (cont.) 
790.4/23.4 (22079) 0.047 0.012 
613.3/22.0 (13465) 0.042 -0.068 
713.4/32.6 (19574) 0.040 0.021 
550.6/31.4 (8956) 0.037 0.031 
1891.1/38.9 (23747) 0.035 -0.004 
 
 
Table S 13 - Loading values of each variable on the first two principal components. The contributions are sorted in descending 
order along PC1(Significant loadings >0.229). 
Peak Name PC1 (87.6 %) PC2 (7.3 %) 
793.4/38.8 (22143) 0.436 0.039 
793.9/38.8 (22151) 0.403 0.079 
1049.1/38.9 (23574) 0.354 0.164 
1048.6/38.9 (23572) 0.336 0.157 
538.8/39.0 (8385) 0.310 0.005 
554.3/45.2 (9160) 0.252 0.849 
1303.7/38.8 (23650) 0.216 0.109 
1304.2/38.9 (23651) 0.204 0.087 
1559.9/38.8 (23689) 0.167 0.219 
1559.4/39.0 (23688) 0.158 0.122 
513.3/34.5 (7246) 0.148 -0.109 
487.1/36.1 (6256) 0.140 0.073 
1558.9/38.7 (23687) 0.134 0.077 
792.4/38.9 (22123) 0.127 -0.081 
473.1/33.3 (5865) 0.093 -0.097 
486.1/36.1 (6230) 0.085 -0.051 
1814.0/39.0 (23720) 0.082 0.026 
627.3/22.9 (14456) 0.078 -0.113 
493.2/39.1 (6445) 0.065 -0.287 
 
